BioRestorative Therapies (BRTX) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 30, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1505497
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$5,692,745
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		37,149,052

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$91,798	$201,098
Inventories	1,945	17,965
Prepaid expenses and other current assets	20,570	20,739
Total Current Assets	114,313	239,802
Property and equipment, net	493,856	35,568
Intangible assets, net	1,037,732	1,107,545
Security deposit	45,900	0
Total Assets	1,691,801	1,382,915
Current Liabilities:
Accounts payable	1,111,879	1,269,970
Accrued expenses and other current liabilities	1,466,506	1,176,662
Accrued interest	94,026	65,909
Current portion of notes payable, net of debt discount of $113,257 and $237,381 at December 31, 2014 and 2013, respectively	5,688,239	4,990,009
Deferred revenues	164,349	0
Total Current Liabilities	8,524,999	7,502,550
Accrued interest, non-current portion	5,195	41,434
Notes payable, non-current portion, net of debt discount of $0 and $3,110 at December 31, 2014 and 2013, respectively	50,000	524,000
Total Liabilities	8,580,194	8,067,984
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares (see Note 10); none issued and outstanding at December 31, 2014 and 2013	0	0
Common stock, $0.001 par value; Authorized, 200,000,000 shares (see Note 10); Issued 34,511,800 and 19,633,173 shares at December 31, 2014 and 2013, respectively; Outstanding 33,953,179 and 19,074,552 shares at December 31, 2014 and 2013, respectively	34,512	19,633
Additional paid-in capital	18,509,121	13,139,712
Accumulated deficit	-25,400,026	-19,812,414
Treasury stock, at cost, 558,621 shares at December 31, 2014 and 2013	-32,000	-32,000
Total Stockholders' Deficiency	-6,888,393	-6,685,069
Total Liabilities and Stockholders' Deficiency	$1,691,801	$1,382,915

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current portion of notes payable, debt discount	$113,257	$237,381
Non-current portion of notes payable, debt discount	$0	$3,110
Preferred stock, par value	$0.01	$0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, Authorized	200,000,000	200,000,000
Common stock, Issued	34,511,800	19,633,173
Common stock, Outstanding	33,953,179	19,074,552
Treasury stock, at cost, shares	558,621	558,621

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues	$415,996	$1,680
Cost of sales	213,834	208
Gross Profit	202,162	1,472
Operating Expenses
Marketing and promotion	125,626	114,951
Consulting	1,310,121	779,462
Research and development	1,430,614	1,594,054
General and administrative	2,258,307	2,265,275
Total Operating Expenses	5,124,668	4,753,742
Loss From Operations	-4,922,506	-4,752,270
Other (Expense) Income
Interest expense	-285,275	-371,281
Amortization of debt discount	-464,470	-405,531
Loss on extinguishment of note and payables, net	-49,094	-7,200
Warrant modification expense	-50,035	-214,912
Gain on settlement of notes and payables	183,768	0
Total Other Expense	-665,106	-998,924
Net Loss	($5,587,612)	($5,751,194)
Net Loss Per Share - Basic and Diluted	($0.22)	($0.35)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	25,538,075	16,526,793

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (USD $)	Total	Cash	Common Stock and Warrants	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Additional paid-in capital	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Accumulated deficit	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock	Treasury Stock
			Cash						Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements		Cash	Shares and warrant issued as debt discount in connection with notes payable	Shares and warrants issued in exchange of notes payable and accrued interest	Shares issued as debt discount in connection with notes payable	Leasehold Improvements
Beginning Balance at Dec. 31, 2012	($5,141,693)							$15,443					$8,936,084						($14,061,220)						($32,000)
Beginning Balance (in shares) at Dec. 31, 2012								15,443,484																	-558,621
Stock issued		905,000	841	573,769	417,681				339	819				904,159	573,430	416,862				0	0	0				0	0	0
Stock issued (in shares)			840,589						338,750	818,495																0	0	0
Shares issued in satisfaction of accrued interest	213,000							266					212,734
Shares issued in satisfaction of accrued interest (in shares)								266,250
Shares issued in satisfaction of accrued consulting services																			0						0
Shares issued in satisfaction of accrued consulting services (in shares)																									0
Warrant modification	214,912							0					214,912						0						0
Waiver of previously accrued executive salary and bonus	565,000							0					565,000						0						0
Exercise of warrants for purchase of common stock	505,809							1,686					504,123						0						0
Exercise of warrants for purchase of common stock (in shares)								1,686,029																	0
Beneficial conversion features related to convertible notes payable	0
Stock-based compensation: shares of common stock	138,055							239					137,816						0						0
Stock-based compensation: shares of common stock (in shares)								239,537																	0
Stock-based compensation: options and warrants	674,592							0					674,592						0						0
Impact of share rounding as a result of reverse stock split								39																	0
Net loss	-5,751,194							0					0						-5,751,194
Ending Balance at Dec. 31, 2013	-6,685,069							19,633					13,139,712						-19,812,414						-32,000
Ending Balance (in shares) at Dec. 31, 2013								19,633,173																	-558,621
Stock issued		2,605,000	8,672		343,026	249,800	71,050			1,101	1,000	284		2,596,328		341,925	248,800	70,766		0		0	0	0		0		0	0	0
Stock issued (in shares)			8,671,983							1,101,453	1,000,000	284,200														0		0	0	0
Shares issued in satisfaction of accrued consulting services	140,000							595					139,405						0						0
Shares issued in satisfaction of accrued consulting services (in shares)								595,455																	0
Warrant modification	50,035							0					50,035						0						0
Exercise of warrants for purchase of common stock	113,000							377					112,623						0						0
Exercise of warrants for purchase of common stock (in shares)								376,667																	0
Conversion of notes payable and accrued interest into common stock	359,711							1,785					357,926						0						0
Conversion of notes payable and accrued interest into common stock (in shares)								1,784,777																	0
Beneficial conversion features related to convertible notes payable	92,370							0					92,370						0						0
Stock-based compensation: shares of common stock	300,837							1,065					299,772						0						0
Stock-based compensation: shares of common stock (in shares)								1,064,092																	0
Stock-based compensation: options and warrants	1,059,459							0					1,059,459						0						0
Net loss	-5,587,612							0					0						-5,587,612						0
Ending Balance at Dec. 31, 2014	($6,888,393)							$34,512					$18,509,121						($25,400,026)						($32,000)
Ending Balance (in shares) at Dec. 31, 2014								34,511,800																	-558,621

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($5,587,612)	($5,751,194)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	464,470	405,531
Accretion of interest expense	24,934	5,066
Depreciation and amortization	96,685	104,811
Loss on sale of property and equipment	1,009	0
Stock-based compensation	1,360,296	812,647
Loss on extinguishment of note and payables, net	49,094	7,200
Gain on settlement of notes and payables	-183,768	0
Inventory write-down	15,407	0
Warrant modification expense	50,035	214,912
Warrant issued in connection with note payable	0	9,400
Changes in operating assets and liabilities:
Inventories	613	-5,481
Prepaid expenses and other current assets	11,219	-2,306
Security deposit	-45,900	0
Accounts payable	-234,563	498,541
Accrued interest, expenses and other current liabilities	585,881	1,028,469
Deferred revenues	164,349	0
Total Adjustments	2,359,761	3,078,790
Net Cash Used in Operating Activities	-3,227,851	-2,672,404
Cash Flows From Investing Activities
Purchases of property and equipment	-168,376	-11,160
Proceeds from sale of property and equipment	980	0
Net Cash Used In Investing Activities	-167,396	-11,160
Cash Flows From Financing Activities
Proceeds from notes payable	795,000	1,454,000
Repayments of notes payable	-202,063	-5,500
Advances from director and officer	58,054	144,285
Repayment of advances from director and officer	-83,044	-119,295
Proceeds from exercise of warrants	113,000	505,809
Sales of common stock and warrants for cash	2,605,000	905,000
Net Cash Provided by Financing Activities	3,285,947	2,884,299
Net (Decrease) Increase In Cash	-109,300	200,735
Cash - Beginning	201,098	363
Cash - Ending	91,798	201,098
Cash paid during the period for:
Interest	127,112	62,346
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	359,711	0
Recharacterization of accrued interest as principal with note payable reissuance	108,059	68,100
Beneficial conversion features set up as debt discount	92,370	0
Waiver of previously accrued executive salary and bonus	0	565,000
Accrued purchases of property and equipment	258,774	0
Shares Issued in Connection with Notes Payable Extension
Non-cash investing and financing activities:
Shares issued	249,800	564,369
Shares Issued in Satisfaction of Accrued Interest
Non-cash investing and financing activities:
Shares issued	0	213,000
Shares issued in satisfaction of accrued interest
Non-cash investing and financing activities:
Shares issued	343,026	417,681
Shares and warrant issued to satisfy lease obligation and leasehold improvements
Non-cash investing and financing activities:
Shares issued	71,050	0
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Shares issued	$140,000	$0

Business_Organization_and_Natu

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations
	BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which the Company formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells designed for personal medical applications. BRT’s website is at www.biorestorative.com. BRT is currently pursuing a Disc/Spine Program. Its lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes and has labeled this initiative its ThermoStem® Program. It is a pre-clinical cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue and is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans." BRT has developed an ingredient derived from human adult stem cells, which can be used by third party companies in the development of their own skin care products. The ingredient was developed pursuant to BRT’s “brtx-C Cosmetic Program”. BRT’s Stem Pearls® brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at  www.stempearls.com.
	Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015.
	Effective April 15, 2013, pursuant to authority granted by the stockholders to the Board of Directors of the Company, the Company implemented a 1-for-50 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 1,500,000,000 to 100,000,000. All share and per share information in these consolidated financial statements has been retroactively adjusted to reflect the Reverse Split. See Note 10 – Stockholders’ Deficiency for additional details regarding the Company’s authorized capital.

Going_Concern_and_Managements_

Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2014
Development Stage Enterprises [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans
	As of December 31, 2014, the Company had a working capital deficiency and a stockholders’ deficiency of $8,410,686 and $6,888,393, respectively. During the years ended December 31, 2014 and 2013, the Company incurred net losses of $5,587,612 and $5,751,194, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	Despite recent revenue generated from specific research and development contracts, the Company's primary source of operating funds since inception has been, and will continue to be for the foreseeable future, equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
	The accompanying consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
	Subsequent to December 31, 2014, (a) the Company has raised an aggregate of $801,000 and $30,000 through equity financing and debt financing, respectively, (b) the Company has received research and development payments of $227,234 and (c) $50,000 and $5,984 of debt and accrued interest, respectively, has been converted into common stock. As a result, the Company expects to be able to fund its operations through April 2015. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $5,000 which are either past due or payable on demand. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 11– Subsequent Events for additional details.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
	Concentrations and Credit Risk
	As of December 31, 2014, 75% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”) and the maturity dates associated with these notes range from May 7, 2015 to June 30, 2015. See Note 7 – Notes Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below.
	Cash
	The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
	Inventories
	The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method.
	The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $15,407.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred.
	Intangible Assets
	Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years (20 year life of underlying patents which the Company is licensing, less 2.3 years elapsed since the application date of the respective patents), respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis.
	Impairment of Long-lived Assets
	The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
	Revenue Recognition
	Research and Development Agreements
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method);  (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $250,000 payment and the first two quarterly payments of $89,063 related to (2) above had been received and $130,068 was recorded as deferred revenues on the consolidated balance sheet.
	During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $413,777. The Company did not recognize any revenue related to research and development agreements during the year ended December 31, 2013.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	For the years ended December 31, 2014 and  2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $2,219 and $1,680, respectively.
	Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
	The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.
	The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		December 31,
		2014		2013
	Options		15,584,000		5,043,000
	Warrants		8,248,683		4,795,890
	Convertible notes		653,885		1,063,380
	Total potentially dilutive shares		24,486,568		10,902,270
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
	Advertising
	Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $15,280 and $25,748, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations.
	Research and Development
	Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $1,430,614 and $1,594,054, respectively.
	Reclassifications
	Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.
	Fair Value of Financial Instruments
	The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
	Convertible Instruments
	GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements.
In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment
	Property and equipment include the following:
		December 31,
		2014		2013
	Office equipment	$	8,466	$	7,670
	Medical equipment		359,248		129,461
	Furniture and fixtures		113,874		19,322
	Computer software and equipment		66,458		20,169
	Leasehold Improvements		103,582		-
			651,628		176,622
	Less: accumulated depreciation		-157,772		-141,054
	Property and equipment, net	$	493,856	$	35,568
	Depreciation expense amounted to $26,872 and $34,999 for the years ended December 31, 2014 and 2013, respectively. Depreciation expense is reflected in general and administrative expenses in the consolidated statements of operations.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Intangible Assets	Note 5 – Intangible Assets
	Intangible assets consist of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization		Total
	Balance as of January 1, 2013	$	3,676	$	1,226,500	$	-52,819	$	1,177,357
	Amortization expense		-		-		-69,812		-69,812
	Balance as of December 31, 2013	$	3,676	$	1,226,500	$	-122,631	$	1,107,545
	Amortization expense		-		-		-69,813		-69,813
	Balance as of December 31, 2014	$	3,676	$	1,226,500	$	-192,444	$	1,037,732
	Weighted average remaining amortization period at December 31, 2014 in years		6		14.9
	Amortization of intangible assets consists of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization
	Balance as of January 1, 2013	$	736	$	52,083	$	52,819
	Amortization expense		368		69,444		69,812
	Balance as of December 31, 2013	$	1,104	$	121,527	$	122,631
	Amortization expense		368		69,445		69,813
	Balance as of December 31, 2014	$	1,472	$	190,972	$	192,444
	Amortization expense is reflected in general and administrative expenses in the consolidated statements of operations. Based upon the current intangible assets as of December 31, 2014, amortization expense is projected to be approximately $70,000 per annum through 2029.
	On January 27, 2012, the Company entered into a license agreement with a stem cell treatment company (“SCTC”) (as amended on March 21, 2012, the “SCTC Agreement”). On April 6, 2012 (the “Closing Date”), the Company and SCTC closed on the SCTC Agreement. Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from SCTC to utilize or sublicense a certain medical device patent (pending) for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. The SCTC Agreement provides that the Company must achieve certain milestones. As of December 31, 2014, the Company had not met any the milestones provided for in the SCTC Agreement to be fulfilled by April 6, 2014; however, it still had the ability to pay  $75,000 by April 6, 2015 in order to retain the exclusivity of the license. On March 5, 2015, the Company made the $75,000 cash payment to retain the exclusivity of the license. Pursuant to the license agreement with SCTC, unless certain milestones are satisfied, the Company will be required to pay to SCTC minimum amounts of between $225,000 and $475,000 during the period from April 2017 to April 2019 in order to maintain its exclusive rights with regard to the disc/spine technology.
	The SCTC Agreement also provides for an exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use for orthopedic purposes and a non-exclusive, royalty-bearing sublicense of certain of the licensed technology to SCTC for use (1) at a single facility in the Cayman Islands (or, under certain circumstances, at a different non-U.S. facility), and (2) at U.S. facilities (in accordance with protocols established by the Company), if and only if, upon resolution of a Food and Drug Administration (“FDA”) action, SCTC has the legal right to exploit the technology in the U.S. and the Company does not yet have such legal right. Further, the SCTC Agreement provides that SCTC will furnish certain training, assistance and consultation services with regard to the licensed technology. In addition, the Company had agreed to reimburse SCTC for 25% of its legal fees associated with what had been a pending court action with the FDA, subject to a maximum of $4,500 per month and $100,000 in the aggregate. In 2012, the District Court ruled in favor of the FDA, but SCTC appealed the decision. In February 2014, the United States Court of Appeals for the D.C. Circuit affirmed the District Court’s ruling, concluding that the FDA has the authority to regulate certain autologous stem cell procedures and that SCTC’s stem cell mixture meets the definition of drug and not HCT/P since it was more than minimally manipulated. SCTC has indicated that it does not intend to appeal the decision to the Supreme Court. While this decision is specific to SCTC’s procedures and mixture, it indicates that stem cells, even when used in an autologous context, may be regulated as drugs, particularly when mixed with other substances or in other ways that may be considered to be more than minimally manipulated. The Company is proceeding with the FDA approval process for its initiatives as discussed above.
	Pursuant to the SCTC Agreement, on the Closing Date, the Company made a payment to SCTC consisting of a license fee of $1,000,000, net of a sublicensing fee of $10,000, which SCTC owed to the Company (which was recorded as revenue in the consolidated statements of operations), and issued to SCTC a warrant for the purchase of 1,000,000 shares of common stock of the Company (the “SCTC Warrant”). The vesting of the SCTC Warrant was divided into three tranches. The first tranche to purchase 300,000 shares of common stock was immediately exercisable. The exercise of the second and third tranches to purchase 350,000 shares of common stock each is subject to specified performance criteria. The exercise price for the initial tranche is $1.50 per share and the exercise price for the second and third tranches is the greater of $1.50 per share or the then fair market value of the common stock, as defined in the SCTC Agreement. The initial tranche had a grant date value of $226,500 using the Black-Scholes model, which was recognized immediately. The Company recorded the $1,000,000 cash payment and the $226,500 value of the first tranche of the warrant as an intangible asset with an original estimated useful life of 17.7 years (20 year life of the underlying pending patent less 2.3 years since patent application).
	The Company has not made an accounting entry related to the second and third tranches as it is not currently estimable when the specified performance criteria will be met. When, and if, the second and third tranches of the SCTC Warrant vest (or when the timing of vesting becomes estimable), the grant date value of these tranches will be added to the value of the intangible asset after calculating the grant date values using the Black-Scholes option pricing model using the final exercise prices as inputs to the model.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 6 – Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities are comprised of the following:
		December 31,
		2014		2013
	Credit card payable	$	4,739	$	6,000
	Accrued payroll and payroll taxes		679,277		672,535
	Accrued purchases of property and equipment		174,801		-
	Accrued research and development expenses		292,395		229,276
	Accrued general and administrative expenses		315,294		266,541
	Deferred rent		-		2,310
	Total	$	1,466,506	$	1,176,662
	During the year ended December 31, 2014, the Company received an aggregate of $58,054 in non-interest bearing advances from a director, an officer and a family member of the same officer and made aggregate repayments of $83,044 (inclusive of the $24,990 outstanding balance as of December 31, 2013 discussed below), such that the Company had no remaining liability with regard to these advances as of December 31, 2014. During the year ended December 31, 2013, the Company received an aggregate of $144,285 in advances from a director, an officer and a family member of the same officer and made aggregate repayments of $119,295, such that the Company had a liability of $24,990 with regard to these advances as of December 31, 2013.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	Note 7 – Notes Payable
	A summary of the notes payable activity during the years ended December 31, 2014 and 2013 is presented below:
			Bermuda		Convertible			Other			Debt
			Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2012		$	3,550,000	$	-		$	1,082,185		$	-76,719		$	4,555,466
	Issuances			450,000		281,000	[1]		733,000			-			1,464,000
	Conversion of accrued interest			-		-			68,100			-			68,100
	Exchanges for equity			-		-			-404,285			-			-404,285
	Repayments			-		-			-5,500			-			-5,500
	Recognition of debt discount			-		-			-			-574,369	[1]		-574,369
	Amortization of debt discount			-		-			-			405,531			405,531
	Accretion of interest expense			-		-			-			5,066	[1]		5,066
	Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
	Issuances			500,000		300,000	[1]		-			-			800,000
	Exchanges for equity			-		-71,000			-203,000			-			-274,000
	Conversions to equity			-		-342,500			-			-			-342,500
	Repayments			-89,063		-			-113,000			-			-202,063
	Recognition of debt discount			-		-			-			-347,170	[1]		-347,170
	Amortization of debt discount			-		-			-			464,470			464,470
	Recharacterization of accrued interest as principal			-		-			108,059	[3]		-			108,059
	Accretion of interest expense			-		15,000	[2]		-			9,934	[1]		24,934
	Settlement of accreted interest			-		-7,500	[2]		-			-			-7,500
	Outstanding, December 31, 2014		$	4,410,937	$	175,000	[4]	$	1,265,559		$	-113,257		$	5,738,239
		[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
		[2]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
		[3]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $752,500 to $860,559.
		[4]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
	Bermuda Lender
	On March 26, 2013, Cayman borrowed $450,000 from the Bermuda Lender, which was combined with the already outstanding $3,550,000 of previous borrowings from the Bermuda Lender into a new $4,000,000 zero coupon note (the “$4,000,000 Bermuda Lender Note”) which matured on July 31, 2014. In consideration of the additional $450,000 loan, the waiver of accrued and unpaid interest of $213,000, and an extension of the maturity date of the outstanding loan, the Company issued to the Bermuda Lender 600,000 shares of common stock (valued at $480,000) and a five year warrant to purchase 400,000 shares of common stock at an exercise price of $2.50 per share (valued at $250,000). After determining that 266,250 shares of common stock (of the 600,000 shares issued) were, in effect, used to settle the aggregate $213,000 accrued and unpaid interest, the Company determined that the relative fair value of the remaining equity securities issued was $457,826, which amount was recorded as a debt discount and was amortized via the interest method over the sixteen month term of the $4,000,000 Bermuda Lender Note in accordance with ASC 470-60. The effective annual interest rate of the $4,000,000 Bermuda Lender Note is 11%.
	On May 8, 2014, Cayman borrowed an additional $500,000 from the Bermuda Lender and issued to the Bermuda Lender a one-year note payable in the principal amount of $500,000 which bears interest at 15% per annum payable at maturity. The note also provides for the mandatory prepayment of the principal amount to the extent of any monies received by the Company pursuant to the research and development agreements discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. Interest on the entire principal amount of the note is payable until such time as the principal amount is paid in full. On July 15, 2014, the Company received $89,063 pursuant to the research and development agreements which triggered a mandatory principal prepayment of $89,063. See Note 11 – Subsequent Events for details regarding monies received pursuant to the research and development agreements.
	On August 13, 2014, Cayman and the Bermuda Lender agreed to extend the maturity date of the $4,000,000 Bermuda Lender Note from July 31, 2014 to December 31, 2014. In consideration of the extension, the Company issued to the Bermuda Lender 550,000 shares of common stock. The $121,000 fair value of the common stock was recorded as debt discount and was amortized over the remaining term of the $4,000,000 Bermuda Lender Note.
	On December 31, 2014, Cayman and the Bermuda Lender agreed to further extend the maturity date of the $4,000,000 Bermuda Lender Note from December 31, 2014 to June 30, 2015. In consideration of the extension, the Company issued to the Bermuda Lender 450,000 shares of common stock. The $99,000 fair value of the common stock was recorded as debt discount and will be amortized over the remaining term of the $4,000,000 Bermuda Lender Note.
	As of December 31, 2014, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock.
	Convertible Notes
	Between August 8, 2013 and December 18, 2013, the Company issued convertible notes with an aggregate principal amount of $281,000, for cash consideration of $271,000 (convertible notes with an aggregate principal amount of $60,000 bear no interest and were issued for cash consideration of $50,000 and the $10,000 of interest, was recorded as debt discount and will be amortized over the term of the note, resulting in a weighted average effective interest rate of 100%). Convertible notes with an aggregate principal amount of $221,000 bear interest at a rate of 12% per annum payable upon maturity. The convertible notes were initially payable 2-6 months from the date of issuance. Of the $281,000 principal amount of convertible notes, $171,000 are convertible into shares of the Company’s common stock at the election of the Company while $110,000 are convertible into shares of the Company’s common stock at the election of the holder. The convertible notes are convertible during the period beginning five days prior to maturity and ending on the day immediately prior to maturity (the “Note Conversion Period”). The conversion price of the convertible notes is equal to the greater of (a) 55-65% (depending on the specific note) of the fair value of the Company’s common stock or (b) $0.05 per share. As of December 31, 2013, the convertible notes were not convertible. The Company evaluated the conversion options and determined that bifurcation was not necessary in accordance with ASC 815. The beneficial conversion features will be accounted for, if necessary, at the commitment date.
	Between January 17, 2014 and May 2, 2014, the Company issued convertible notes with an aggregate principal amount of $175,000, for cash consideration of $170,000 (a convertible note with a principal amount of $30,000 bears no interest and was issued for cash consideration of $25,000 and the $5,000 difference was recorded as debt discount and was accreted as interest over the term of the note). Convertible notes with an aggregate principal amount of $145,000 bear interest at a rate of 12% per annum payable upon maturity. The convertible notes were initially payable 3-12 months from the date of issuance. Of the $175,000 principal amount of convertible notes, $145,000 is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55%-60% (depending on the particular note) of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
	Between November 12, 2014 and December 2, 2014, the Company issued convertible notes in the aggregate principal amount of $125,000 which bear interest at a rate of 10% per annum payable on maturity. The convertible notes are payable as follows: (i) $41,667 of aggregate principal and the respective accrued interest on such principal is payable six months from the issuance date (the “First Maturity Date”), (ii) $41,667 of principal and the respective accrued interest on such principal is payable two weeks following the First Maturity Date (the “Second Maturity Date”), and (iii) $41,666 of principal and the respective accrued interest on such principal is payable one month following the First Maturity Date (the “Third Maturity Date”). Each $41,667 and $41,666 of aggregate principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at the greater of (a) 60% of the fair value of the Company’s stock or (b) $0.05 per share. In the event that the Company elects to effect a conversion, during the five day period following the conversion, the holders shall have the right to convert the then outstanding principal amount of the convertible notes, together with accrued and unpaid interest thereon, into shares of the Company’s common stock at a conversion price equal to the conversion price in the Company-effected conversion.
	During the year ended December 31, 2014, the Company elected to convert certain convertible notes with an aggregate principal balance of $225,000 and aggregate accrued interest of $13,565 into an aggregate of 1,202,744 shares of common stock at conversion prices ranging from $0.14 to $0.28 per share.
	During the year ended December 31, 2014, the holders of certain convertible notes elected to convert such convertible notes with an aggregate principal balance of $117,500 and aggregate accrued interest of $3,646 into an aggregate of 582,033 shares of common stock at conversion prices ranging from $0.19 to $0.22 per share.
	During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $71,000, along with accrued and unpaid interest of $4,260, for an aggregate of 246,764 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The common stock and warrants had an aggregate grant date value of $74,029 and, as a result, the Company recorded a gain on extinguishment of $1,231. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
	During the year ended December 31, 2014, the contingently adjustable conversion ratios associated with certain convertible notes were resolved. The Company estimated the intrinsic value of the embedded conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the year ended December 31, 2014, the Company recognized $92,370 of intrinsic value related to these beneficial conversion features as debt discount which was immediately amortized.
	Other Notes
	Other notes issued by the Company (“Other Notes”) predominantly bear interest at a rate of 15% per annum payable monthly. As of December 31, 2014, the Other Notes have maturity dates through October 2015.
	The holders of two Other Notes are entitled to five years of royalty payments associated with Cosmetic Revenues, as defined in the notes, ranging from 0.5% to 4.0% of Cosmetic Revenues, depending on the holder and the year the Cosmetic Revenues are earned. The final three years of royalty payments are subject to an annual dollar maximum of $100,000 for one of the noteholders. Given that the Company has not yet generated any Cosmetic Revenues, no royalty payments have been earned.
	In connection with the issuance and extension of Other Notes during the year ended December 31, 2013, the Company issued 5,000 shares of common stock, with a relative fair value of $3,704. In connection with the issuances, five-year warrants to purchase an aggregate of 402,500 shares of common stock at exercise prices ranging from $0.94 to $2.50 per share, with a relative fair value of $112,239, were issued as debt discount to the lenders and amortized over the term of the note.
	In connection with the extension of Other Notes during the year ended December 31, 2014, the Company issued five-year warrants to purchase an aggregate of 190,000 shares of common stock at exercise prices ranging from $0.50 to $0.75 per share, with a grant date fair value of $29,800, as debt discount to the lenders and amortized over the term of the note.
	During the year ended December 31, 2013, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $404,285, along with accrued and unpaid interest of $6,196, for an aggregate of 818,495 shares of common stock and five-year warrants to purchase an aggregate of 45,000 shares of common stock at an exercise price of $1.50 per share. The stock and warrants had an aggregate issuance date value of $417,681 and, as a result, the Company recorded a loss on extinguishment of $7,200. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
	During the year ended December 31, 2014, the Company and certain lenders agreed to exchange certain Other Notes with an aggregate principal balance of $203,000, along with accrued and unpaid interest of $15,672, for an aggregate of 854,689 shares of common stock and an immediately vested, two-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.75 per share. The common stock and warrants had an aggregate grant date value of $268,997 and, as a result, the Company recorded a loss on extinguishment of $50,325. The lenders received piggyback registration rights related to the stock and the stock issuable pursuant to the warrants.
	During the year ended December 31, 2014, the Company repaid certain Other Notes with an aggregate principal balance of $113,000 and accrued interest of $11,219.
	See Note 11 – Subsequent Events for additional details regarding notes payable.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes
	United States and foreign components of loss before income taxes were as follows:
		For The Years Ended
		December 31,
		2014			2013
	United States	$	-5,223,749		$	-5,328,958
	Foreign		-363,863			-422,236
	Loss before income taxes	$	-5,587,612		$	-5,751,194
	The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:
		For The Years Ended
		December 31,
		2014			2013
	Deferred Tax Assets:
	Net operating loss carryforward	$	4,820,500		$	5,327,000
	Stock-based compensation		1,272,600			907,100
	Accruals		240,700			139,800
	Research & development tax credits		95,500			-
	Other		2,100			2,700
	Gross deferred tax assets		6,431,400			6,376,600
	Deferred Tax Liabilities:
	Fixed assets		-93,200			-
	Intangible assets		-8,100			-3,000
	Gross deferred tax liabilities		-101,300			-3,000
	Net deferred tax assets		6,330,100			6,373,600
	Valuation allowance		-6,330,100			-6,373,600
	Deferred tax asset, net of valuation allowance	$	-		$	-
	Changes in valuation allowance	$	-43,500		$	1,631,300
	The income tax provision (benefit) consists of the following:
		For The Years Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		38,921			-1,459,584
	State and local:
	Current		-			-
	Deferred		4,579			-171,716
			43,500			-1,631,300
	Change in valuation allowance		-43,500			1,631,300
	Income tax provision (benefit)	$	-		$	-
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		For The Years Ended
		December 31,
		2014				2013
	Tax benefit at federal statutory rate		-34	%			-34	%
	State income taxes, net of federal benefit		-4	%			-4	%
	Permanent differences		0.8	%			5.8	%
	Research & development tax credits		-1.8	%			0	%
	Impact of Section 382 limit		41.2	%			0	%
	True-ups and other		-1.4	%			1.6	%
	Change in valuation allowance		-0.8	%			30.6	%
	Effective income tax rate		0	%			0	%
	The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.
	At December 31, 2014 and 2013, the Company had approximately $12,700,000 and $14,000,000, respectively, of federal and state net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forwards are subject to annual limitations due to greater than 50% ownership changes. The Section 382 limitation that became effective on or about July 2014 has resulted in (a) approximately $5,700,000 of federal NOLs not being realizable; and (b) the reversal of approximately $2,200,000 of net operating loss deferred tax assets.
	The Company files income tax returns in the U.S. federal jurisdiction and the states of Florida and New York, and is subject to examination by the various taxing authorities beginning with the tax years ended December 31, 2011.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies
	Operating Lease
	Jupiter, Florida Lease
	The Company was a party to  a three year lease agreement with respect to premises located at the Alexandria Innovation Center in Jupiter, Florida, which was scheduled to expire on January 31, 2014. No base rent was payable during the initial year and the lease provided for a base monthly rent of $6,234 during the second year and $6,422 during the third year. The Company had the right to lease the premises for an additional three years at the then fair market value rent. The aggregate base rent payable over the lease term was recognized on a straight-line basis.
	On February 4, 2014, the Company and the landlord agreed to the surrender of a portion of the leased premises and also extended the term of the lease to July 31, 2014. The amended lease provided for a base rent of $962 per month. The Company and the landlord subsequently agreed to a series of lease extensions, such that the lease ultimately terminated on December 31, 2014.
	On February 11, 2014, the Company executed a Facility Use Agreement with the SCTC which permitted the Company to utilize the SCTC’s laboratory facility and one office for research associated with its culturing and medical device license. Payment terms were $3,750 per month through March 31, 2014 and $100 per day for usage beyond that date. The Company ceased using the SCTC’s laboratory facility on March 31, 2014.
	On August 25, 2014, the Company entered into a lease for 6,800 square feet of space located in Melville, New York (the “Melville Lease”). Late in 2014, the Company relocated its corporate and laboratory operations from Jupiter, Florida to such location. The Melville Lease provides for a term of 63 months from the commencement date (as defined in the Melville Lease) (subject to extension at the option of the Company for a period of five years) and an annual base rental during the initial term ranging between $132,600 and $149,260. Pursuant to the Melville Lease, no rent was payable for the initial four months of the term.
	In connection with the Melville Lease, the Company paid the landlord a cash security deposit of $45,900, which is reflected on the consolidated balance sheet as of December 31, 2014. Additionally, in connection with the execution of the Melville Lease, the Company issued to the principals of the landlord an aggregate of 284,200 shares of its common stock and five-year warrants to purchase an aggregate of 142,100 shares of its common stock at an exercise price of $0.50 per share as consideration for: (i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease. During the year ended December 31, 2014, the Company has (i) recorded a credit to equity for the $71,050 value of the common stock and warrants, (ii) capitalized $60,000 of leasehold improvements which is included within property and equipment, net on the consolidated balance sheet as of December 31, 2014, and will be amortized over the term of the lease and (iii) recorded prepaid rent of $11,050 within prepaid expenses and other current assets on the consolidated balance sheet as of December 31, 2014, which will be expensed following the fifth month of the lease.
	Rent expense amounted to $20,380 and $99,175 for the years ended December 31, 2014 and 2013, respectively. Rent expense is reflected in general and administrative expenses in the consolidated statements of operations.
	Litigations, Claims and Assessments
	In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.
	In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff is seeking to recover an unspecified amount of damages but at least approximately $193,000 of cash (or alternatively $52,000 per year from September 2009) as well as the repayment of the alleged loan with interest, reimbursement for certain out-of-pocket fees and expenses, two weeks vacation pay per year, and the issuance of 80,000 shares of the Company’s common stock or warrants for the purchase of 80,000 shares of the Company’s common stock (or alternatively the market value of such securities). A trial of the action is scheduled to commence in June 2015. On March 13, 2015, the Company filed with the court a settlement offer in an amount which has been accrued.
	The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.
	Research Agreements
	Effective June 15, 2012, the Company entered into an assignment agreement (the “Assignment Agreement”) with the research foundation of a state university (the “Foundation”), whereby the Foundation assigned all of its right, title and interest in specified patents to the Company in exchange for a cash payment of $15,000. The Company also agreed to pay the Foundation a 5% royalty on Patent Revenue (as defined in the Assignment Agreement) over a 20 year period commencing on June 15, 2012. Through December 31, 2014, no royalties have been earned.
	Effective June 15, 2012, the Company entered into a research agreement (the “Research Agreement”) with the same state university (the “University”). The Research Agreement has a term of three years. Pursuant to the Research Agreement, the University agreed to perform certain research services to be used by the Company. Pursuant to the Research Agreement, the Company agreed to pay the University a fee of $500,000 for each twelve month period of the agreement, payable monthly. In addition, the Company agreed to pay to the University a 5% royalty, over a 20 year period commencing on June 15, 2012, on the net sales of all products and/or methods directly arising from inventions and improvements conceived or reduced to practice by the University in the course of performing research during the term of the Research Agreement. The Research Agreement can be cancelled without penalty upon (a) the second anniversary of the Research Agreement if eventual FDA approval does not appear likely or (b) other conditions specified in the Research Agreement. Through December 31, 2014, no royalties have been earned.
	On May 9, 2014, the Company entered into an amendment to the Research Agreement. Pursuant to the amendment, the parties agreed that (i) no fees are payable by the Company to the University pursuant to the Research Agreement for the first five monthly payments in 2014 ($208,335 of fees in total were cancelled, of which, $104,168 was accrued for as of March 31, 2014), (ii) effective with the payment due on June 15, 2014, the monthly fee payable by the Company to the University pursuant to the Research Agreement will be reduced from $41,667 to $20,000 and (iii) the scope of the work to be performed by the University pursuant to the Research Agreement was reduced. The Research Agreement, as amended, is scheduled to expire on June 14, 2015. Concurrent with the execution of the amendment, the Company paid $323,336 to the University, representing the balance due of all fees payable by the Company to date pursuant to the Research Agreement. As a result of the above, the Company recorded an immediate gain on settlement in the amount of $166,668.
	During the years ended December 31, 2014 and 2013, the Company recorded research and development expense of approximately $264,000 and $500,000, respectively in connection with the Research Agreement. As of December 31, 2014 and 2013, the Company had accrued approximately $43,000 and $353,000, respectively, in connection with the Research Agreement, which is included in accounts payable and accrued expenses and other current liabilities in the consolidated balance sheets.
	Consulting Agreements
	Marketing Consulting Services
	On June 27, 2014, a February 17, 2011 agreement for marketing consulting services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Marketing Consulting Term”). In consideration of services rendered during the New Marketing Consulting Term and the settlement of the Company’s obligation to pay $65,000 in cash to the consultant, the Company issued to a designee of the consultant 500,000 shares of common stock and issued to the consultant an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The common stock and warrant had grant date values of $110,000 and $37,500, respectively, which were recognized immediately. During the years ended December 31, 2014 and 2013, the Company recorded consulting expense of $82,500 and $120,000, respectively, related to the marketing consulting agreement.
	Consulting Services
	On February 20, 2014, the Company executed a two-year consulting agreement with the Physiatrist-In-Chief Emeritus for the Hospital for Special Surgery in New York City to become the Company’s Chief Medical Advisor for Spine Medicine pursuant to which he oversees the clinical aspects of the brtxDISC™ Program. The agreement may be terminated earlier or extended, as provided for in the agreement. Pursuant to the agreement, the consultant is entitled to receive $10,000 per month, escalating to $20,000 per month upon the FDA approval of the Company’s Investigational New Drug or Investigational Device Exemption application with respect to its brtxDISC™ Program. In addition, the Company granted the consultant a five-year option to purchase 300,000 shares of common stock at an exercise price of $0.65 per share, pursuant to the Plan. The option vests ratably over three years on the grant date anniversaries and the grant date value of $67,830 will be recognized proportionate to the vesting period. On October 8, 2014, the consulting agreement between the Company and its Chief Medical Advisor for Spine Medicine was amended such that the consultant will be entitled to receive $15,000 per month (and eliminated the possible increase to $20,000 per month). In connection with the amendment, the consultant was issued a five-year option to purchase 500,000 shares of the Company’s common stock at an exercise price of $0.32 per share. The option vests ratably over three years on the grant date anniversaries and the grant date value of $124,200 will be recognized proportionate to the vesting period.
	On March 12, 2014, as additional compensation for consulting services rendered, the Company granted to a consultant an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.53 per share. In addition, warrants to purchase an aggregate of 280,000 shares of common stock had their exercise prices reduced to $0.53 per share from $1.50 per share and such warrants, as well as a warrant to purchase 20,000 shares of common stock, had their term extended to March 12, 2019. The grant date value of the issued warrant of $23,270 along with the incremental value related to the modification of the outstanding warrants of $30,096 was recognized during the year ended December 31, 2014 as stock-based compensation expense, which is reflected as consulting expense in the consolidated statements of operations.
	On July 23, 2014, the Company entered into a one-year agreement with a consultant to market research and development arrangements and other business transactions to potential strategic partners and other alliance candidates. In exchange for services provided by the consultant during the term, the Company agreed to issue 30,000 shares of common stock of the Company for each complete month during the term. During the year ended December 31, 2014, the Company issued to the consultant an aggregate 150,000 shares of common stock and the aggregate grant date value of $33,000 was recognized immediately.
	On October 7, 2014, the Company entered into an agreement with a consultant for services regarding the search for a President for the Company’s Disc/Spine Division. The consultant was entitled to an initial retainer fee of $15,000, payable in shares of the Company’s common stock, and a second retainer fee of $10,000 to be paid in cash. A final fee will be invoiced upon a selected candidate’s acceptance of BRT’s offer and commencement of employment equal to 28% of the candidate’s first year base salary less the initial $25,000 retainer fee. Pursuant to the agreement, the Company issued 48,388 shares of common stock related to the initial retainer to the consultant and the $15,000 grant date value was reflected as consulting expense in the consolidated statements of operations. See Note 11 – Subsequent Events for additional details.
	Business Advisory Services
	On June 27, 2014, a February 17, 2011 agreement for business advisory services that had expired on December 31, 2013 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of April 1, 2014 and provided for an expiration date of December 31, 2014 (the “New Business Advisory Term”). In consideration of services rendered during the New Business Advisory Term, the Company agreed to pay a cash fee of $16,667 per month and the Company granted an immediately vested five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.00 per share. The warrant had a grant date value of $37,500 which was recognized immediately. On August 27, 2014, the Company and the consultant entered into an agreement pursuant to which the consultant waived the Company’s obligation to pay $75,000 of accrued cash compensation to the consultant, in exchange for 300,000 shares of the Company’s common stock. On December 19, 2014, the agreement was further amended such that the term of the agreement was extended an additional six months until June 30, 2015. During the additional six-month period, the Company agreed to pay a cash fee of $15,000 per month and the Company granted an immediately vested five-year warrant to purchase 100,000 shares of common stock at an exercise price of $0.50 per share. The warrant had a grant date value of $17,000 which was recognized immediately. During the years ended December 31, 2014 and 2013, the Company recorded cash consulting fee expense of $150,000 and $120,000, respectively, related to the business advisory agreement.
	Scientific Advisory Services
	On March 27, 2013, the Company granted a ten-year option to a member of its Scientific Advisory Board to purchase 60,000 shares of common stock at an exercise price of $1.50 per share, pursuant to the Plan. The shares vest as follows: (i) 30,000 shares immediately and (ii) 30,000 shares on the first anniversary of the grant date. The grant date value of $45,900 was recognized half immediately and half proportionate to the vesting period.
	On June 10, 2013, the Company granted a five-year option to a member of its Scientific Advisory Board to purchase 5,000 shares of immediately-vested common stock at an exercise price of $1.00 per share, pursuant to the Plan. The grant date value of $2,056 was recognized immediately.
	On July 2, 2013, the Company granted a ten-year option to a member of its Scientific Advisory Board to purchase 100,000 shares of common stock at an exercise price of $1.00 per share, pursuant to the Plan. The shares vest as follows: (i) 50,000 shares immediately and (ii) 50,000 shares on the first anniversary of the grant date. The grant date value of $47,960 was recognized half immediately and half proportionate to the vesting period.
	On March 14, 2014, the Company executed an agreement, which will continue until terminated by either party, appointing a new Scientific Advisory Board member. Pursuant to the agreement, the Company immediately granted the new advisor a five-year option to purchase 25,000 shares of common stock at an exercise price of $0.50 per share, pursuant to the Plan. The option vests as follows: (i) 12,500 shares immediately and (ii) 12,500 shares on the first anniversary of the grant date. In addition, on each annual anniversary date of the agreement, the advisor is entitled to a new five-year option to purchase 5,000 shares of the Company’s common stock at an exercise price equal to the then fair market value of the common stock. The option grant date value of $5,860 will be recognized proportionate to the vesting period.
	On June 27, 2014, an August 16, 2012 agreement for scientific advisory services was further extended to August 16, 2016 such that the consultant will continue to serve as Chairman of the Company’s Scientific Advisory Board, will earn $10,000 per month and will be entitled to specified expense reimbursements. In addition, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The option vests as follows: (i) 150,000 shares on August 16, 2015 and (ii) 150,000 shares on August 16, 2016. The option grant date value of $81,000 will be recognized proportionate to the vesting period.
	Other
	On March 20, 2013, the Company granted an immediately vested, three-year warrant to purchase 10,000 shares of common stock at an exercise price of $1.50 per share to a consultant. The grant date value of $6,600 was recognized immediately.
	On March 22, 2013, the Company granted an immediately vested, five-year warrant to purchase 100,000 shares of common stock at an exercise price of $4.00 per share as consideration for legal services. The grant date value of $59,000 was recognized immediately.
	On December 23, 2013, the Company granted immediately vested, five-year warrants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $2.00 per share to consultants. The aggregate grant date value of $16,770 was recognized immediately.
	On July 22, 2014, the Company granted a consultant an immediately vested five-year warrant to purchase 10,000 shares of common stock at an exercise price of $0.75 per share. The aggregate grant date value of $1,500 was recognized immediately.
	In addition to the issuances discussed elsewhere in this filing, during the years ended December 31, 2014 and 2013, an aggregate of 474,373 and 129,537 shares of immediately vested common stock valued at $159,837 and $77,555, respectively, were issued to consultants for various services rendered to the Company.
	Employment Agreements
	Chief Executive Officer
	Effective December 2013, the Company and its Chief Executive Officer (“CEO”) agreed that the CEO’s 2013 salary would be reduced from $600,000 to $360,000 and that his 2013 bonus of $300,000 and his 2013 vacation pay of $25,000 would be waived. As a result, the Company imputed the value of the services contributed and recorded salary expense of $565,000 for the year ended December 31, 2013 with a corresponding credit to stockholders’ deficiency.
	During the year ended December 31, 2014, the Company and its CEO approved amendments to the employment agreement between the Company and the CEO, dated October 4, 2010, as amended, providing for (a) a reduction of the CEO’s annual salary from $600,000 to $450,000, effective October 1, 2014, and (b) a reduction of the CEO’s annual salary from $450,000 to $400,000, effective January 1, 2015. During the years ended December 31, 2014 and 2013, the Company recorded $450,000 and $600,000, respectively, in operating expenses with regard to the CEO’s base salary.
	As of December 31, 2014 and 2013, the accrued and unpaid compensation (salary, bonus, tax liability, car allowance and vacation pay) for the CEO was $574,278 and $542,535, respectively, and was included in accrued expenses and other current liabilities in the consolidated balance sheets. See Note 11– Subsequent Events for additional details.
	Other
	In addition to the Company’s employment agreement with its CEO, as of December 31, 2014, two employees have “at-will” employment agreements with the Company that currently provide for aggregate cash severance payments of $175,000, payable over twelve months, upon involuntary termination. See Note 11– Subsequent Events for additional details.
	Board of Directors
	On June 27, 2014, a director of the Company resigned due to other business commitments. In consideration of director services performed to date, the Company agreed to pay an aggregate of $80,000 (of which, $50,000 was previously earned and accrued for), payable as follows: (i) $30,000 immediately and (ii) the $50,000 balance in six equal monthly installments commencing on July 31, 2014. In addition, all outstanding options held by the director which were not exercisable as of the date of resignation became exercisable on the earlier of (i) the date on which such options were scheduled to become exercisable or (ii) December 31, 2014, and all outstanding options shall remain exercisable until their respective expiration dates notwithstanding the director’s resignation. As a result of the modification of the options, the Company recorded incremental stock-based compensation expense of $96,250.
	On June 27, 2014, the Company elected two new directors. Concurrent with the election, the Company granted the new directors ten-year options to purchase an aggregate of 600,000 shares of common stock at an exercise price of $0.285 per share, pursuant to the Plan. The options vest as follows: (i) an aggregate of 200,000 shares on the date of grant; (ii) an aggregate of 200,000 shares on the first anniversary of the date of grant; and (iii) an aggregate of 200,000 shares on the second anniversary of the date of grant. The options have an aggregate grant date value of $144,000 which will be recognized proportionate to the vesting period.
	As of December 31, 2014 and 2013, $105,000 and $130,000 of director cash compensation, respectively, was outstanding and included in accrued expenses and other current liabilities in the consolidated balance sheets.
	Related Party Agreement
	Effective October 1, 2014, the Company entered into a three-month agreement with an affiliate of one of its directors for consulting services related to the Company’s brtxDISC™ Program and ThermoStem® Program. Pursuant to the agreement, the affiliate of the director was entitled to a cash fee of $10,000 per month and an amount of common stock having a fair market value of $5,000 as of the last day of each month during the term. On December 19, 2014, the agreement was amended such that the term of the agreement was extended until March 31, 2015. During the year ended December 31, 2014, the Company issued 36,786 shares of common stock pursuant to the agreement with a grant date fair value of $15,000.

Stockholders_Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 10 – Stockholders’ Deficiency
	Authorized Capital
	As of December 31, 2014, the Company was authorized to issue 100,000,000 shares of common stock, $0.001 par value, and 1,000,000 shares of preferred stock, $0.01 par value. The holders of the Company’s common stock are entitled to one vote per share. Subject to the rights of holders of preferred stock, if any, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Subject to the rights of holders of preferred stock, if any, upon liquidation, dissolution or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available for distribution.
	On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000; and (ii) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 1,000,000 to 5,000,000.
	2010 Equity Participation Plan
	On February 18, 2014 and October 23, 2014, the Board of Directors of the Company approved successive increases in the number of shares of common stock authorized to be issued pursuant to the Plan from 6,000,000 to 12,000,000 and then to 20,000,000. On December 19, 2014, the Company’s shareholders approved an increase in the number of shares of common stock authorized to be issued pursuant to the Plan to 20,000,000.
	Common Stock and Warrant Offerings
	During the year ended December 31, 2013, the Company issued an aggregate of 840,589 shares of common stock at prices ranging from $0.85 to $1.50 per share to investors for aggregate gross proceeds of $905,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 403,590 shares of common stock at exercise prices ranging from $1.50 to $4.00 per share of common stock. The warrants had an aggregate grant date value of $224,313.
	During the year ended December 31, 2014, the Company issued an aggregate of 8,671,983 shares of common stock at prices ranging from $0.25 to $0.45 per share to investors for aggregate gross proceeds of $2,605,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 2,330,693 shares of common stock at exercise prices ranging from $0.30 to $0.75 per share of common stock. The warrants have terms ranging from two to five years. The warrants had an aggregate grant date value of $389,608.
	See Note 7 – Notes Payable for details associated with common stock issued in conjunction with the extension and exchange of notes payable and related accrued interest.
	See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with common stock issued in conjunction with consulting agreements.
	Warrant and Option Valuation
	The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the years ended December 31, 2014 and 2013. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
	Warrant Exercise and Reload Program
	On November 27, 2013, the Company initiated a limited time program (the “Warrant Exercise and Reload Program”) which, at the election of any warrant holder, would permit them to immediately exercise their outstanding exercisable warrants at an exercise price of $0.30 per share. In connection with the exercise of the warrant, in addition to having received the number of shares pursuant to such exercise, each holder received a new warrant for the same number of shares purchased with an exercise price of $0.75 per share and an expiration date two years from the date of grant. The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days. Under the Warrant Exercise and Reload Program, warrants to purchase an aggregate of 376,667 and 1,686,029 shares of common stock were exercised during the years ended December 31, 2014 and 2013, respectively, for aggregate gross proceeds of $113,000 and $505,809, respectively. The Company recognized a warrant modification charge of $50,035 and $214,912 during the years ended December 31, 2014 and 2013, respectively, which represents the incremental value of the modified warrant and new warrant combined, as compared to the original warrant value, all valued as of the respective modification dates.
	Stock Warrants
	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions:
			For The Year Ended
			December 31,
			2014				2013
	Risk free interest rate			0.39% - 2.20	%			0.34% - 1.68	%
	Expected term (years)			1.96 - 5.00				3.00 - 5.00
	Expected volatility			116% - 122	%			132% - 135	%
	Expected dividends			0	%			0	%
	The weighted average estimated fair value of the warrants granted during the years ended December 31, 2014 and 2013 was approximately $0.17 and $0.36 per share, respectively.
	See Note 7 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 10 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings.
	The Company recorded stock–based compensation expense of $185,266 and $26,777 during the years ended December 31, 2014 and 2013, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the consolidated statements of operations. As of December 31, 2014, there was no unrecognized stock-based compensation expense related to stock warrants.
	A summary of the warrant activity during the years ended December 31, 2014 and 2013 is presented below:
										Weighted
						Weighted				Average
						Average				Remaining			Aggregate
			Number of			Exercise				Life			Intrinsic
			Warrants			Price				In Years			Value
	Outstanding, December 31, 2012			3,334,800		$	1.69
	Granted			3,147,119			1.56
	Exercised			-1,686,029			0.3	[1]
	Forfeited			-			-
	Outstanding, December 31, 2013			4,795,890		$	1.39
	Granted			3,849,460			0.7
	Exercised			-376,667			0.3	[1]
	Forfeited			-20,000			0.5
	Outstanding, December 31, 2014			8,248,683		$	0.9				3.2		$	-
	Exercisable, December 31, 2014			7,548,683		$	0.84				3.3		$	-
		[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.
	The following table presents information related to stock warrants at December 31, 2014:
	Warrants Outstanding						Warrants Exercisable
							Weighted
							Average			Exercisable
	Exercise			Number of			Remaining Life			Number of
	Price			Warrants			In Years			Warrants
	$	0.3			650,000			4.4			650,000
		0.4			200,000			4.9			200,000
		0.5			502,100			4.8			502,100
		0.53			380,000			3.4			380,000
		0.58			50,000			4.8			50,000
		0.75			4,043,389			2.8			4,043,389
		0.94			50,000			4.8			50,000
		1			550,000			4.4			550,000
		1.5			862,800			2.5			862,800
		1.75			20,000			2.3			20,000
		2			123,530			3.9			123,530
		2.5			20,000			2.6			20,000
		3			36,864			3.3			36,864
		4			60,000			2.8			60,000
	Variable	[1]		700,000			-			-
				8,248,683			3.3			7,548,683
	[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
Stock Options
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
		For the Year Ended
		December 31,
		2014				2013
Risk free interest rate			1.50% - 2.54	%			1.13% - 2.66	%
Expected term (years)			5.00 - 10.00				5.00 - 10.00
Expected volatility			116% - 122	%			132% - 135	%
Expected dividends			0	%			0	%
The weighted average estimated fair value of the stock options granted during the years ended December 31, 2014 and 2013 was approximately $0.27 and $0.26 per share, respectively.
See Note 9 – Commitments and Contingencies for details associated with certain grants of options as compensation to employees, directors and consultants.
On October 4, 2013, the Company granted ten-year options to employees, directors, and an advisor to purchase an aggregate of 980,000 shares of common stock at an exercise price of $0.60 per share, pursuant to the Plan. The shares vest as follows: (i) 490,000 shares immediately and (ii) 490,000 shares on the first anniversary of the grant date. The grant date value of $199,921 was recognized proportionate to the vesting period.
Between February 18, 2014 and March 12, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 2,415,000 shares of common stock at exercise prices ranging from $0.53 to $0.65 per share, pursuant to the Plan. The shares vest as follows: (i) 831,669 shares immediately and (ii) 1,589,331 shares ratably over two years on the grant date anniversaries. The aggregate grant date value of $566,483 will be recognized proportionate to the vesting period.
On June 16, 2014, the Company granted a five-year option to a consultant to purchase 60,000 shares of common stock at an exercise price of $0.39 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $18,600 was recognized proportionate to the vesting period.
On September 24, 2014, the Company granted a five-year option to a consultant to purchase 75,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three months on the grant date anniversaries. The grant date value of $20,100 was recognized proportionate to the vesting period.
On October 23, 2014, the Company granted ten-year options to employees and directors to purchase an aggregate of 5,950,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $1,710,400 will be recognized proportionate to the vesting period.
On October 27, 2014, the Company granted a ten-year option to an advisor to purchase 250,000 shares of common stock at an exercise price of $0.34 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $78,500 will be recognized proportionate to the vesting period.
On November 17, 2014, the Company granted a ten-year option to an employee to purchase 100,000 shares of common stock at an exercise price of $0.33 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries. The grant date value of $31,600 will be recognized proportionate to the vesting period.
The following table presents information related to stock option expense:
												Weighted
												Average
		For the Year Ended						Unrecognized at				Amortization
		December 31,						December 31,				Period
		2014			2013			2014				(Years)
Consulting		$	365,825		$	160,894		$	654,956				2.6
Research and development			328,740			251,758			712,551	[1]			2.5
General and administrative			179,628			235,163			961,378				2.6
		$	874,193		$	647,815		$	2,328,885				2.6
	[1]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.
As of December 31, 2014, there was $2,328,885 of unrecognized compensation expense which will be amortized over the weighted average remaining vesting period of 2.6 years.
A summary of the option activity during the years ended December 31, 2014 and 2013 is presented below:
							Weighted
					Weighted		Average
					Average		Remaining				Aggregate
		Number of			Exercise		Life				Intrinsic
		Options			Price		In Years				Value
Outstanding, December 31, 2012			4,018,000		$	1.12
Granted			1,145,000			0.68
Exercised			-			-
Forfeited			-120,000			0.5
Outstanding, December 31, 2013			5,043,000		$	1.03
Granted			10,575,000			0.41
Exercised			-			-
Forfeited			-34,000			1.31
Outstanding, December 31, 2014			15,584,000		$	0.61			8.5		$	979,600
Exercisable, December 31, 2014			6,371,502		$	0.91			7.6		$	45,600
The following table presents information related to stock options at December 31, 2014:
Options Outstanding						Options Exercisable
						Weighted
			Outstanding			Average			Exercisable
Exercise			Number of			Remaining Life			Number of
Price			Options			In Years			Options
$	0.285			900,000			9.5			200,000
	0.32			500,000			-			-
	0.33			6,125,000			4.7			75,000
	0.34			250,000			-			-
	0.39			60,000			4.5			60,000
	0.5			345,000			4.9			332,500
	0.53			40,000			9.2			40,000
	0.6			980,000			8.8			980,000
	0.65			2,675,000			9.1			1,125,002
	1			131,000			8			131,000
	1.05			2,270,000			7.1			2,270,000
	1.1			5,000			2.4			5,000
	1.2			10,000			1.4			10,000
	1.25			43,000			1.9			43,000
	1.4			350,000			4.5			200,000
	1.5			900,000			7.9			900,000
				15,584,000			7.6			6,371,502
Compensatory Common Stock Issuances
See Note 9 – Commitments and Contingencies for details associated with certain issuances of common stock as compensation to employees, directors and consultants.
On October 4, 2013, the Company issued 50,000 shares of immediately vested common stock to its legal counsel. The $12,500 grant date fair value was recognized immediately.
Between June 27, 2014 and December 31, 2014, the Company issued 150,000 shares of immediately vested common stock to its legal counsel. The $33,000 grant date fair value was recognized immediately.
The following table presents information related to compensatory common stock issuances expense during the years ended December 31, 2014 and 2013:
		For the Year Ended						Unrecognized at
		December 31,						December 31,
		2014			2013			2014
Consulting		$	276,500		$	111,351		$	-
Research and development			24,337			26,704			-
		$	300,837		$	138,055		$	-
A summary of compensatory common stock issuances activity during the years ended December 31, 2014 and 2013 is presented below:
					Weighted
					Average			Total
		Number of			Issuance Date			Issuance Date
		Shares			Fair Value			Fair Value
Non-vested, December 31, 2012			-		$	-		$	-
Granted			239,537			0.58			138,055
Vested			-239,537			0.58			-138,055
Forfeited			-			-			-
Non-vested, December 31, 2013			-		$	-		$	-
Granted			1,943,747			0.26			511,886
Vested			-1,943,747			-0.26			-511,886
Forfeited			-			-			-
Non-vested, December 31, 2014			-		$	-		$	-

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 11 - Subsequent Events
	Research and Development Agreements; Bermuda Lender
	Subsequent to December 31, 2014, the Company received the third and fourth payments of four quarterly payments in the aggregate amount of $177,234 pursuant to the research and development agreement with a U.S. pharmaceutical company discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. This payment triggered the mandatory principal prepayment of $177,237 of the note payable that was issued to the Bermuda Lender on May 8, 2014. As of the filing date of this report, $266,297 of mandatory prepayments to the Bermuda Lender related to the research agreement were unpaid.
	Subsequent to December 31, 2014, the Company received payment in the amount of $50,000 pursuant to the research and development agreement with a Japanese pharmaceutical company discussed in Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements. As of the filing date of this report, a $50,000 mandatory prepayment to the Bermuda Lender related to the research and development agreement was unpaid.
	Short Term Advances
	Subsequent to December 31, 2014, the Company received an aggregate of $60,055 in non-interest bearing advances from an officer and made aggregate repayments of $60,055.
	Notes Payable
	Subsequent to December 31, 2014, the Company issued a convertible note with a principal amount of $30,000 which bears interest at a rate of 12% annum payable upon maturity. The convertible note, is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55% of the fair value of the Company’s stock or (b) $0.10 per share.
	Subsequent to December 31, 2014, the Company elected to convert a convertible note with a principal balance of $50,000 and accrued interest of $5,984 into 222,245 shares of common stock at a conversion price of $0.25 per share.
	Notes payable, non-current portion represents notes payable that were either exchanged for equity or whose maturities were extended past December 31, 2015 after the balance sheet date but before the consolidated financial statements were issued. Accrued interest, non-current portion represents the accrued interest that, after the balance sheet date but before the consolidated financial statements were issued, was either exchanged for equity or converted into the principal amount of a note payable classified as non-current.
	Employment Agreements
	On February 9, 2015, the Company hired a President for its Disc/Spine Division. As compensation the Company granted to the President of its Disc/Spine Division a ten-year option to purchase 500,000 shares of common stock at an exercise price of $0.46 per share, pursuant to the Plan. The shares vest annually over three years on the grant date anniversaries.
	On March 9, 2015, the Company and the CEO agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. Pursuant to the employment agreement, in the event that the CEO’s employment is terminated by the Company without “cause”, or the CEO terminates his employment for “good reason” (each as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). In addition, pursuant to the employment agreement, the CEO would be entitled to receive such severance in the event that the term of his employment agreement is not extended beyond December 31, 2017 and, within three months of such expiration date, his employment is terminated by the Company without “cause” or the CEO terminates his employment for any reason. Further, in the event that the CEO’s employment is terminated by the Company without “cause”, or the CEO terminates his employment for “good reason”, following a “change in control” (as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).
	On March 9, 2015, the Company agreed to amend the at will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment of $125,000.
	Common Stock and Warrant Offerings
	Subsequent to December 31, 2014, the Company issued an aggregate of 2,703,333 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for aggregate gross proceeds of $801,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 850,833 shares of common stock at exercise prices ranging from $0.40 to $0.75 per share of common stock. The warrants have a term of five years. In connection with the common stock and warrant offerings, a previously outstanding warrant to purchase 80,000 shares of common stock at an exercise price of $0.75 per share had its expiration date extended from December 31, 2015 to December 31, 2016.
	Stock-Based Compensation
	Subsequent to December 31, 2014, the Company issued an aggregate of 270,295 shares of common stock valued at $73,528 to consultants pursuant to consulting agreements.
	On January 23, 2015, the Company granted a five-year option to consultants to purchase an aggregate 100,000 shares of common stock at an exercise price of $0.47 per share, pursuant to the Plan. The shares vest as follows: (i) 75,000 shares vest ratably over three months on the grant date anniversaries, (ii) 12,500 shares vest immediately and (iii) 12,500 shares vest on the grant date anniversary.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk
	As of December 31, 2014, 75% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”) and the maturity dates associated with these notes range from May 7, 2015 to June 30, 2015. See Note 7 – Notes Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2014. See Revenue Recognition – Research and Development Agreements below.
Cash	Cash
	The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
Inventories	Inventories
	The Company maintains finished goods inventories, consisting of Stem Pearls skincare products, which are available for sale. Inventories are stated at the lower of cost or market. Cost is determined by the first-in, first-out method.
	The Company periodically reviews for slow-moving, excess or obsolete inventories. Products that are determined to be obsolete, if any, are written down to net realizable value. During the year ended December 31, 2014, the Company recorded an inventory write-down of $15,407.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred.
Intangible Assets	Intangible Assets
	Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years (20 year life of underlying patents which the Company is licensing, less 2.3 years elapsed since the application date of the respective patents), respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis.
Impairment of Long-lived Assets	Impairment of Long-lived Assets
	The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company has not identified any such impairment losses.
Revenue Recognition	Revenue Recognition
	Research and Development Agreements
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	On March 19, 2014, the Company entered into a one-year agreement with a Japanese pharmaceutical company to perform specified research and development activities related to stem cells. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $150,000 received at commencement (straight-line method);  (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	On March 24, 2014, the Company entered into a two-year agreement with a U.S. pharmaceutical company to perform specified research and development activities related to brown fat. The agreement may be terminated earlier or extended, as provided for in the agreement. Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable. As of December 31, 2014, the initial $250,000 payment and the first two quarterly payments of $89,063 related to (2) above had been received and $130,068 was recorded as deferred revenues on the consolidated balance sheet.
	During the year ended December 31, 2014, the Company recognized revenue related to research and development agreements of $413,777. The Company did not recognize any revenue related to research and development agreements during the year ended December 31, 2013.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	For the years ended December 31, 2014 and  2013, the Company recognized revenue related to sales of Stem Pearls® skincare products of $2,219 and $1,680, respectively.
Income Taxes	Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.
	The Company adopted the provisions of Accounting Standards Codification (“ASC”) Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.
	The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
Net Loss Per Common Share	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		December 31,
		2014		2013
	Options		15,584,000		5,043,000
	Warrants		8,248,683		4,795,890
	Convertible notes		653,885		1,063,380
	Total potentially dilutive shares		24,486,568		10,902,270
Stock-Based Compensation	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTC Bulletin Board. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Advertising	Advertising
	Advertising costs are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred advertising costs of $15,280 and $25,748, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations.
Research and Development	Research and Development
	Research and development expenses are charged to operations as incurred. For the years ended December 31, 2014 and December 31, 2013, the Company incurred research and development expenses of $1,430,614 and $1,594,054, respectively.
Reclassifications	Reclassifications
	Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
Convertible Instruments	Convertible Instruments
	GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 11.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The standard requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
	In June 2014, the FASB issued ASU No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation,” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the ASC, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company adopted ASU 2014-10 during the year ended December 31, 2014 which resulted in the removal of previously required development stage disclosures. The Company’s planned principal operations are to develop technology using cell and tissue therapy protocols, primarily involving adult stem cells, allowing patients to undergo cellular-based treatments. The Company has established a new laboratory facility and is seeking to increase its capabilities for the further development of possible cellular-based treatment protocols, stem cell-related intellectual property and research applications. The Company’s activities are subject to significant risks and uncertainties, which are detailed in Note 2 – Going Concern and Management’s Plans.
	In June 2014, the FASB issued ASU No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of ASU 2014-12 will have a material impact on its consolidated financial statements.
	In August 2014, the FASB issued ASU No. 2014-15,”Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company elected to adopt ASU 2014-15. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2 – Going Concern and Management’s Plans.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		December 31,
		2014		2013
	Options		15,584,000		5,043,000
	Warrants		8,248,683		4,795,890
	Convertible notes		653,885		1,063,380
	Total potentially dilutive shares		24,486,568		10,902,270

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment include the following:
		December 31,
		2014		2013
	Office equipment	$	8,466	$	7,670
	Medical equipment		359,248		129,461
	Furniture and fixtures		113,874		19,322
	Computer software and equipment		66,458		20,169
	Leasehold Improvements		103,582		-
			651,628		176,622
	Less: accumulated depreciation		-157,772		-141,054
	Property and equipment, net	$	493,856	$	35,568

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Intangible Assets [Abstract]
Schedule Of Intangible Assets By Major Class	Intangible assets consist of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization		Total
	Balance as of January 1, 2013	$	3,676	$	1,226,500	$	-52,819	$	1,177,357
	Amortization expense		-		-		-69,812		-69,812
	Balance as of December 31, 2013	$	3,676	$	1,226,500	$	-122,631	$	1,107,545
	Amortization expense		-		-		-69,813		-69,813
	Balance as of December 31, 2014	$	3,676	$	1,226,500	$	-192,444	$	1,037,732
	Weighted average remaining amortization period at December 31, 2014 in years		6		14.9
Schedule Of FiniteLived Intangible Assets Amortization Expense	Amortization of intangible assets consists of the following:
		Patents and				Accumulated
		Trademarks		Licenses		Amortization
	Balance as of January 1, 2013	$	736	$	52,083	$	52,819
	Amortization expense		368		69,444		69,812
	Balance as of December 31, 2013	$	1,104	$	121,527	$	122,631
	Amortization expense		368		69,445		69,813
	Balance as of December 31, 2014	$	1,472	$	190,972	$	192,444

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following:
		December 31,
		2014		2013
	Credit card payable	$	4,739	$	6,000
	Accrued payroll and payroll taxes		679,277		672,535
	Accrued purchases of property and equipment		174,801		-
	Accrued research and development expenses		292,395		229,276
	Accrued general and administrative expenses		315,294		266,541
	Deferred rent		-		2,310
	Total	$	1,466,506	$	1,176,662

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	A summary of the notes payable activity during the years ended December 31, 2014 and 2013 is presented below:
			Bermuda		Convertible			Other			Debt
			Lender		Notes			Notes			Discount			Total
	Outstanding, December 31, 2012		$	3,550,000	$	-		$	1,082,185		$	-76,719		$	4,555,466
	Issuances			450,000		281,000	[1]		733,000			-			1,464,000
	Conversion of accrued interest			-		-			68,100			-			68,100
	Exchanges for equity			-		-			-404,285			-			-404,285
	Repayments			-		-			-5,500			-			-5,500
	Recognition of debt discount			-		-			-			-574,369	[1]		-574,369
	Amortization of debt discount			-		-			-			405,531			405,531
	Accretion of interest expense			-		-			-			5,066	[1]		5,066
	Outstanding, December 31, 2013		$	4,000,000	$	281,000		$	1,473,500		$	-240,491		$	5,514,009
	Issuances			500,000		300,000	[1]		-			-			800,000
	Exchanges for equity			-		-71,000			-203,000			-			-274,000
	Conversions to equity			-		-342,500			-			-			-342,500
	Repayments			-89,063		-			-113,000			-			-202,063
	Recognition of debt discount			-		-			-			-347,170	[1]		-347,170
	Amortization of debt discount			-		-			-			464,470			464,470
	Recharacterization of accrued interest as principal			-		-			108,059	[3]		-			108,059
	Accretion of interest expense			-		15,000	[2]		-			9,934	[1]		24,934
	Settlement of accreted interest			-		-7,500	[2]		-			-			-7,500
	Outstanding, December 31, 2014		$	4,410,937	$	175,000	[4]	$	1,265,559		$	-113,257		$	5,738,239
		[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
		[2]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
		[3]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $752,500 to $860,559.
		[4]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax effects of temporary differences that give rise to deferred tax assets	United States and foreign components of loss before income taxes were as follows:
		For The Years Ended
		December 31,
		2014			2013
	United States	$	-5,223,749		$	-5,328,958
	Foreign		-363,863			-422,236
	Loss before income taxes	$	-5,587,612		$	-5,751,194
	The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:
		For The Years Ended
		December 31,
		2014			2013
	Deferred Tax Assets:
	Net operating loss carryforward	$	4,820,500		$	5,327,000
	Stock-based compensation		1,272,600			907,100
	Accruals		240,700			139,800
	Research & development tax credits		95,500			-
	Other		2,100			2,700
	Gross deferred tax assets		6,431,400			6,376,600
	Deferred Tax Liabilities:
	Fixed assets		-93,200			-
	Intangible assets		-8,100			-3,000
	Gross deferred tax liabilities		-101,300			-3,000
	Net deferred tax assets		6,330,100			6,373,600
	Valuation allowance		-6,330,100			-6,373,600
	Deferred tax asset, net of valuation allowance	$	-		$	-
	Changes in valuation allowance	$	-43,500		$	1,631,300
Income tax provision (benefit)	The income tax provision (benefit) consists of the following:
		For The Years Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		38,921			-1,459,584
	State and local:
	Current		-			-
	Deferred		4,579			-171,716
			43,500			-1,631,300
	Change in valuation allowance		-43,500			1,631,300
	Income tax provision (benefit)	$	-		$	-
Reconciliation of effective tax rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		For The Years Ended
		December 31,
		2014				2013
	Tax benefit at federal statutory rate		-34	%			-34	%
	State income taxes, net of federal benefit		-4	%			-4	%
	Permanent differences		0.8	%			5.8	%
	Research & development tax credits		-1.8	%			0	%
	Impact of Section 382 limit		41.2	%			0	%
	True-ups and other		-1.4	%			1.6	%
	Change in valuation allowance		-0.8	%			30.6	%
	Effective income tax rate		0	%			0	%

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions:
			For The Year Ended
			December 31,
			2014				2013
	Risk free interest rate			0.39% - 2.20	%			0.34% - 1.68	%
	Expected term (years)			1.96 - 5.00				3.00 - 5.00
	Expected volatility			116% - 122	%			132% - 135	%
	Expected dividends			0	%			0	%
Summary of Warrant Activity	A summary of the warrant activity during the years ended December 31, 2014 and 2013 is presented below:
										Weighted
						Weighted				Average
						Average				Remaining			Aggregate
			Number of			Exercise				Life			Intrinsic
			Warrants			Price				In Years			Value
	Outstanding, December 31, 2012			3,334,800		$	1.69
	Granted			3,147,119			1.56
	Exercised			-1,686,029			0.3	[1]
	Forfeited			-			-
	Outstanding, December 31, 2013			4,795,890		$	1.39
	Granted			3,849,460			0.7
	Exercised			-376,667			0.3	[1]
	Forfeited			-20,000			0.5
	Outstanding, December 31, 2014			8,248,683		$	0.9				3.2		$	-
	Exercisable, December 31, 2014			7,548,683		$	0.84				3.3		$	-
		[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.
Information Related to Stock Warrants	The following table presents information related to stock warrants at December 31, 2014:
	Warrants Outstanding						Warrants Exercisable
							Weighted
							Average			Exercisable
	Exercise			Number of			Remaining Life			Number of
	Price			Warrants			In Years			Warrants
	$	0.3			650,000			4.4			650,000
		0.4			200,000			4.9			200,000
		0.5			502,100			4.8			502,100
		0.53			380,000			3.4			380,000
		0.58			50,000			4.8			50,000
		0.75			4,043,389			2.8			4,043,389
		0.94			50,000			4.8			50,000
		1			550,000			4.4			550,000
		1.5			862,800			2.5			862,800
		1.75			20,000			2.3			20,000
		2			123,530			3.9			123,530
		2.5			20,000			2.6			20,000
		3			36,864			3.3			36,864
		4			60,000			2.8			60,000
		Variable	[1]		700,000			-			-
					8,248,683			3.3			7,548,683
		[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
			For the Year Ended
			December 31,
			2014				2013
	Risk free interest rate			1.50% - 2.54	%			1.13% - 2.66	%
	Expected term (years)			5.00 - 10.00				5.00 - 10.00
	Expected volatility			116% - 122	%			132% - 135	%
	Expected dividends			0	%			0	%
Stock option expense	The following table presents information related to stock option expense:
													Weighted
													Average
			For the Year Ended						Unrecognized at				Amortization
			December 31,						December 31,				Period
			2014			2013			2014				(Years)
	Consulting		$	365,825		$	160,894		$	654,956				2.6
	Research and development			328,740			251,758			712,551	[1]			2.5
	General and administrative			179,628			235,163			961,378				2.6
			$	874,193		$	647,815		$	2,328,885				2.6
		[1]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.
Summary of Option Activity	A summary of the option activity during the years ended December 31, 2014 and 2013 is presented below:
								Weighted
						Weighted		Average
						Average		Remaining
			Number of			Exercise		Life				Intrinsic
			Options			Price		In Years				Value
	Outstanding, December 31, 2012			4,018,000		$	1.12
	Granted			1,145,000			0.68
	Exercised			-			-
	Forfeited			-120,000			0.5
	Outstanding, December 31, 2013			5,043,000		$	1.03
	Granted			10,575,000			0.41
	Exercised			-			-
	Forfeited			-34,000			1.31
	Outstanding, December 31, 2014			15,584,000		$	0.61			8.5		$	979,600
	Exercisable, December 31, 2014			6,038,169		$	0.93			7.6		$	45,600
Information Related to Stock Options	The following table presents information related to stock options at December 31, 2014:
	Options Outstanding						Options Exercisable
							Weighted
				Outstanding			Average			Exercisable
	Exercise			Number of			Remaining Life			Number of
	Price			Options			In Years			Options
	$	0.285			900,000			9.5			200,000
		0.32			500,000			-			-
		0.33			6,125,000			4.7			75,000
		0.34			250,000			-			-
		0.39			60,000			4.5			60,000
		0.5			345,000			4.9			332,500
		0.53			40,000			9.2			40,000
		0.6			980,000			8.8			980,000
		0.65			2,675,000			9.1			1,125,002
		1			131,000			8			131,000
		1.05			2,270,000			7.1			2,270,000
		1.1			5,000			2.4			5,000
		1.2			10,000			1.4			10,000
		1.25			43,000			1.9			43,000
		1.4			350,000			4.5			200,000
		1.5			900,000			7.9			900,000
					15,584,000			7.6			6,371,502
Common Stock Award Expense	The following table presents information related to compensatory common stock issuances expense during the years ended December 31, 2014 and 2013:
			For the Year Ended						Unrecognized at
			December 31,						December 31,
			2014			2013			2014
	Consulting		$	276,500		$	111,351		$	-
	Research and development			24,337			26,704			-
			$	300,837		$	138,055		$	-
Summary of Common Stock Award Activity	A summary of compensatory common stock issuances activity during the years ended December 31, 2014 and 2013 is presented below:
						Weighted
						Average			Total
			Number of			Issuance Date			Issuance Date
			Shares			Fair Value			Fair Value
	Non-vested, December 31, 2012			-		$	-		$	-
	Granted			239,537			0.58			138,055
	Vested			-239,537			0.58			-138,055
	Forfeited			-			-			-
	Non-vested, December 31, 2013			-		$	-		$	-
	Granted			1,943,747			0.26			511,886
	Vested			-1,943,747			-0.26			-511,886
	Forfeited			-			-			-
	Non-vested, December 31, 2014			-		$	-		$	-

Business_Organization_and_Natu1

Business Organization and Nature of Operations - Additional Information (Detail)	0 Months Ended
	Apr. 15, 2013	Dec. 31, 2014	Dec. 19, 2014	Dec. 31, 2013
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company implemented a 1-for-50 reverse split
Stockholders equity note, changes in capital structure, retroactive impact	1,500,000,000 to 100,000,000
Changes in capital structure retroactive impact shares	1,500,000,000
Common stock, authorized	100,000,000	200,000,000	20,000,000	200,000,000

Going_Concern_and_Managements_1

Going Concern and Management's Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$8,410,686
Stockholders deficiency	-6,888,393
Net loss	-5,587,612
Note principal and accrued interest converted to equity	-274,000
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through debt financing	30,000
Amount raised through equity financing	801,000
Notes payable aggregate principal past due	5,000
Other Research and Development Expense	227,234
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	5,984
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$50,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended		1 Months Ended		3 Months Ended
	Jul. 15, 2014	Apr. 06, 2012	Dec. 31, 2014	Dec. 31, 2013	Mar. 19, 2014	Mar. 24, 2014	Jun. 30, 2014	Mar. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Debt instrument outstanding face amount percentage			75.00%
Finite-Lived Intangible Asset, Useful Life		17 years 8 months 12 days
Advertising Expense			$15,280	$25,748
Research and Development Expense			1,430,614	1,594,054
Finite Lived Intangible Asset Useful Life From Application Date			2 years 3 months 18 days
Deferred Revenue, Current			164,349	0
Revenues			415,996	1,680
Cash Proceeds From Research Agreements	89,063
Inventory Write-down			15,407	0
Research and Development Agreements One Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms					Payment terms are (1) $150,000 received at commencement (straight-line method); (2) $50,000 upon achievement of a specified deliverable (milestone method); and (3) $50,000 upon achievement of the final specified deliverable (milestone method). As of December 31, 2014, the initial $150,000 payment had been received and $34,281 remained in deferred revenues on the consolidated balance sheet.
Deferred Revenue, Current			150,000
Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms						Payment terms are (1) $250,000 at commencement; (2) $356,250 payable in four equal quarterly installments, subject to acceleration upon achieving a specified deliverable; and (3) $168,750 payable in two equal bi-annual installments (all three of which are being recognized pursuant to the straight-line method), subject to acceleration upon achieving a specified deliverable.
Deferred Revenue, Current			250,000			130,068
Cash Proceeds From Research Agreements							89,063	89,063
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues			413,777
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life			3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life			5 years
Trademarks
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenue, Net, Total			$2,219	$1,680
Licenses
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			17 years 8 months 12 days
Patents
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			20 years
Finite Lived Intangible Asset Useful Life From Application Date			2 years 3 months 18 days

Calculation_of_Weighted_Averag

Calculation of Weighted Average Dilutive Common Shares (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	24,486,568	10,902,270
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	15,584,000	5,043,000
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	8,248,683	4,795,890
Restricted Stock
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	653,885	1,063,380

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$26,872	$34,999

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Office equipment	$8,466	$7,670
Medical equipment	359,248	129,461
Furniture and fixtures	113,874	19,322
Computer software and equipment	66,458	20,169
Leasehold Improvements	103,582	0
Property, Plant and Equipment, Gross	651,628	176,622
Less: accumulated depreciation	-157,772	-141,054
Property and equipment, net	$493,856	$35,568

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended
	Apr. 06, 2012	Dec. 31, 2014	Mar. 05, 2015	Jan. 27, 2012	Oct. 07, 2014	Feb. 20, 2014
Finite-Lived Intangible Assets [Line Items]
Grant date value		$124,200			$15,000	$67,830
Payment capitalized as intangible asset	1,000,000
Estimated useful life	17 years 8 months 12 days
Useful life lapsed since patent application		2 years 3 months 18 days
Amortization		70,000
Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock		80,000
Exercise price of warrant		$0.75
Milestones payment			75,000
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	20 years
First Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock	300,000
Exercise price of warrant	$1.50
Grant date value	226,500
Payment capitalized as intangible asset	226,500
Second Tranche
Finite-Lived Intangible Assets [Line Items]
Warrant Issued To Purchase Common Stock	350,000
Exercise price of warrant	$1.50
Maximum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment			475,000
Minimum | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Milestones payment			225,000
License Agreement Terms
Finite-Lived Intangible Assets [Line Items]
Percentage of legal fees agreed to be reimbursed				25.00%
Net License fee paid	1,000,000
Licenses Revenue	10,000
Warrant Issued To Purchase Common Stock	1,000,000
License Agreement Terms | Maximum
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed				100,000
License Agreement Terms | Maximum | Monthly Payment
Finite-Lived Intangible Assets [Line Items]
Legal fees agreed to be reimbursed				4,500

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	$1,107,545	$1,177,357
Amortization expense	-69,813	-69,812
Ending Balance	1,037,732	1,107,545
Patents and Trademarks
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Amortization expense	0	0
Ending Balance	3,676	3,676
Weighted Average Amortization Period	6 years
Licensing Agreements
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	1,226,500	1,226,500
Amortization expense	0	0
Ending Balance	1,226,500	1,226,500
Weighted Average Amortization Period	14 years 10 months 24 days
Accumulated Amortization
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Beginning Balance	-122,631	-52,819
Amortization expense	-69,813	-69,812
Ending Balance	($192,444)	($122,631)

Amortization_of_Intangible_Ass

Amortization of Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Patents and Trademarks
Accumulated Amortization [Line Items]
Beginning Balance	$1,104	$736
Amortization expense	368	368
Ending Balance	1,472	1,104
Licensing Agreements
Accumulated Amortization [Line Items]
Beginning Balance	121,527	52,083
Amortization expense	69,445	69,444
Ending Balance	190,972	121,527
Accumulated Amortization
Accumulated Amortization [Line Items]
Beginning Balance	122,631	52,819
Amortization expense	69,813	69,812
Ending Balance	$192,444	$122,631

Recovered_Sheet1

Accrued Expenses And Other Current Liabilities - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$58,054	$144,285
Repayment of advances from officer	83,044	119,295
Liability to officer		$24,990

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$4,739	$6,000
Accrued payroll and payroll taxes	679,277	672,535
Deferred rent	0	2,310
Accrued purchases of property and equipment	174,801	0
Accrued research and development expenses	292,395	229,276
Accrued general and administrative expenses	315,294	266,541
Total	$1,466,506	$1,176,662

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended		1 Months Ended	3 Months Ended	4 Months Ended	1 Months Ended
	Aug. 13, 2014	Jul. 15, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 02, 2014	2-May-14	Dec. 18, 2013	Mar. 26, 2013	8-May-14
Debt Instrument [Line Items]
Aggregate principal amount			$83,333	$83,333
Warrants aggregate grant date fair value			389,608	389,608	224,313
Debt instrument, face amount	4,000,000		7,500	7,500
Warrants to purchase common stock			2,330,693	2,330,693	403,590
Loss on extinguishment of note and payables, net				49,094	7,200
Accrued loan interest			108,059	108,059
Stock issued (in shares)	550,000
Common stock aggregate grant date fair value			74,029	74,029	3,704
Warrant Issued During Period Relative Fair Value					112,239
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			190,000	190,000	402,500
Debt Instrument Periodic Payment Interest				15,000
Debt Instrument, Periodic Payment, Principal				175,000
Proceeds from Notes Payable				795,000	1,454,000
Debt Instrument, Convertible, Beneficial Conversion Feature				92,370	0
Debt Instrument, Interest Rate During Period				15.00%
Payments for royalties				100,000
Debt Conversion, Original Debt, Amount				30,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.75	$0.75
Debt Instrument, Maturity Date Range, Start	31-Jul-14			31-Dec-14
Debt Instrument, Maturity Date Range, End	31-Dec-14			30-Jun-15
Amortization Of Debt Discount (Premium)	121,000		99,000	464,470	405,531
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount				71,000
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount				4,260
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable				246,764
Warrants Issued During Period, Number of Warrants1			100,000	100,000
Payments under Research and Development Agreements			113,000	113,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures				11,219
Cash Proceeds From Research Agreements		89,063
Warrants
Debt Instrument [Line Items]
Warrants aggregate grant date fair value			29,800	29,800
Notes Payable
Debt Instrument [Line Items]
Debt Instrument Annual Principal Payment			225,000	225,000
Debt Instrument, Increase, Accrued Interest				13,565
Conversion of Stock, Shares Issued				1,202,744
Notes Payable | Cayman
Debt Instrument [Line Items]
Debt instrument, face amount									3,550,000
First Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal						41,667
Second Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal						41,667
Third Maturity Date
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal						41,666
Minimum
Debt Instrument [Line Items]
Warrants exercise price			$0.30	$0.30	$1.50
Debt Instrument, Periodic Payment, Principal				752,500
Debt Instrument, Increase, Accrued Interest				90,000
Percentage of royalty payments				0.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.50	$0.50	$0.94
Minimum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.14	$0.14
Maximum
Debt Instrument [Line Items]
Warrants exercise price			$0.75	$0.75	$4
Debt Instrument, Periodic Payment, Principal				860,559
Debt Instrument, Increase, Accrued Interest				105,000
Percentage of royalty payments				4.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.75	$0.75	$2.50
Maximum | Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.28	$0.28
In exchange of notes payable
Debt Instrument [Line Items]
Warrants aggregate grant date fair value			268,997	268,997
Warrants exercise price			$0.75	$0.75	$1.50
Loss on extinguishment of note and payables, net				50,325	7,200
Stock issued (in shares)					5,000
Common stock aggregate grant date fair value					417,681
Amortization Of Debt Discount (Premium)				0	0
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Principal Amount				203,000	404,285
Stock Issued During Period, Value, Issued in Exchange of Notes Payable, Interest Amount				15,672	6,196
Stock Issued During Period, Shares, Issued in Exchange of Notes Payable				854,689	818,495
Warrants Issued During Period, Number of Warrants1			100,000	100,000	45,000
Convertible Notes
Debt Instrument [Line Items]
Aggregate principal amount							175,000	281,000
Rate of interest						10.00%	12.00%	12.00%
Loss on extinguishment of note and payables, net				1,231
Debt instrument conversion period description								The conversion price of the convertible notes is equal to the greater of (a) 55-65% (depending on the specific note) of the fair value of the Company’s common stock or (b) $0.05 per share. As of December 31, 2013, the convertible notes were not convertible. The beneficial conversion features will be accounted for, if necessary, at the commitment date.
Debt instrument, new proceeds							170,000	271,000
Debt Instrument Annual Principal Payment			30,000	30,000	60,000		30,000	60,000
Debt Instrument issued for consideration				25,000	50,000		25,000	50,000
Debt Instrument Periodic Payment Interest				5,000	10,000		5,000	10,000
Debt Instrument, Periodic Payment, Principal							145,000	221,000
Debt Instrument, Frequency of Periodic Payment							The convertible notes were initially payable 3-12 months from the date of issuance	Convertible Notes were initially payable 2-6 months from the date of issuance.
Proceeds from Notes Payable						125,000	175,000	281,000
Debt Instrument, Convertible, Beneficial Conversion Feature							145,000	171,000
Debt Instrument Convertible Number of stock to holders								110,000
Debt Instrument, Increase, Accrued Interest				3,646
Debt instrument, interest rate, effective percentage								100.00%
Amortization Of Debt Discount (Premium)				0	0
Conversion of Stock, Shares Issued				582,033
Debt Instrument Issue Description							(a) 55%-60% (depending on the particular note) of the fair value of the Company’s stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Company’s common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Company’s common stock, but with a floor of $0.05 per share.
Convertible Notes | Minimum
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.19	$0.19
Convertible Notes | Maximum
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.22	$0.22
Waiver
Debt Instrument [Line Items]
Aggregate principal amount									450,000
Accrued loan interest									213,000
Bermuda Lender
Debt Instrument [Line Items]
Aggregate principal amount										500,000
Scheduled maturity date of the note									31-Jul-14
Warrants aggregate grant date fair value									457,826
Warrants to purchase common stock									400,000
Warrants exercise price									$2.50
Stock issued (in shares)									600,000
Stock issued, amount									480,000
Fair value Of warrants									250,000
Stock issued during period shares in connection with accrued and unpaid interest									266,250
Debt instrument, interest rate, effective percentage									11.00%	15.00%
Bermuda Lender | Notes Payable | Cayman
Debt Instrument [Line Items]
Aggregate principal amount									450,000
Debt instrument, face amount									$4,000,000

Notes_Payable_Detail

Notes Payable (Detail) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended
	Aug. 13, 2014	Dec. 31, 2014		Dec. 31, 2014		Dec. 31, 2013
Debt Instrument [Line Items]
Balance				$5,514,009		$4,555,466
Issuances				800,000		1,464,000
Conversion of accrued interest						68,100
Exchanges for equity				-274,000		-404,285
Conversions to equity				-342,500
Repayments				-202,063		-5,500
Recognition of debt discount				-347,170		-574,369
Amortization of debt discount	121,000	99,000		464,470		405,531
Recharacterization of accrued interest as principal				108,059
Accretion of interest expense				24,934		5,066
Settlement of accreted interest				-7,500
Balance		5,738,239		5,738,239		5,514,009
Debt Discount
Debt Instrument [Line Items]
Balance				-240,491		-76,719
Issuances				0		0
Conversion of accrued interest						0
Exchanges for equity				0		0
Conversions to equity				0
Repayments				0		0
Recognition of debt discount				-347,170	[1]	-574,369	[1]
Amortization of debt discount				464,470		405,531
Recharacterization of accrued interest as principal				0
Accretion of interest expense				9,934	[1]	5,066	[1]
Settlement of accreted interest				0
Balance		-113,257		-113,257		-240,491
Bermuda Lender Member
Debt Instrument [Line Items]
Balance				4,000,000		3,550,000
Issuances				500,000		450,000
Conversion of accrued interest						0
Exchanges for equity				0		0
Conversions to equity				0
Repayments				-89,063		0
Recognition of debt discount				0		0
Amortization of debt discount				0		0
Recharacterization of accrued interest as principal				0
Accretion of interest expense				0		0
Settlement of accreted interest				0
Balance		4,410,937		4,410,937		4,000,000
Convertible Notes Payable
Debt Instrument [Line Items]
Balance				281,000		0
Issuances				300,000	[1]	281,000	[1]
Conversion of accrued interest						0
Exchanges for equity				-71,000		0
Conversions to equity				-342,500
Repayments				0		0
Recognition of debt discount				0		0
Amortization of debt discount				0		0
Recharacterization of accrued interest as principal				0
Accretion of interest expense				15,000	[2]	0
Settlement of accreted interest				-7,500	[2]
Balance		175,000	[3]	175,000	[3]	281,000
Notes Payable, Other Payables
Debt Instrument [Line Items]
Balance				1,473,500		1,082,185
Issuances				0		733,000
Conversion of accrued interest						68,100
Exchanges for equity				-203,000		-404,285
Conversions to equity				0
Repayments				-113,000		-5,500
Recognition of debt discount				0		0
Amortization of debt discount				0		0
Recharacterization of accrued interest as principal				108,059
Accretion of interest expense				0	[4]	0
Settlement of accreted interest				0
Balance		$1,265,559		$1,265,559		$1,473,500
[1]	During the years ended December 31, 2014 and 2013, notes with an aggregate principal amounts of $30,000 and $60,000, respectively, bear no interest and were issued for cash consideration of $25,000 and $50,000, respectively. The differences between the principal amounts of the notes and the cash received of $5,000 and $10,000, respectively, were recorded as debt discount and amortized to interest expense over the term of the notes.
[2]	During the year ended December 31, 2014, pursuant to the terms of certain notes payable with maturity dates ranging from January 8, 2014 to June 10, 2014, the aggregate principal balance of the notes was increased from $90,000 to $105,000. The aggregate $15,000 of principal increases was accreted as interest expense. During the year ended December 31, 2014, $7,500 of the principal increases was settled by the conversion of a convertible note with a maturity date of January 8, 2014 and original principal balance of $30,000 into shares of the Company's common stock.
[3]	As of December 31, 2014, convertible notes with an aggregate principal balance of $175,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
[4]	During the year ended December 31, 2014, in connection with the extension of certain notes payable with maturity dates ranging from of August 8, 2013 to March 1, 2014, an aggregate $108,059 of accrued interest was added to the aggregate principal balance of the notes, increasing the aggregate principal balance from $742,500 to $850,559.

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Federal and state net operating losses	$12,700,000	$14,000,000
Operating Loss Carry forwards Expiration Period	The net operating loss carry forwards, if not utilized, will expire from 2029 to 2034 for federal purposes.
Percentage of ownership changes	50.00%
Description for Section 382 limitation One	approximately $5,700,000 of federal NOLs not being realizable
Description for Section 382 limitation two	the reversal of approximately $2,200,000 of net operating loss deferred tax assets.

Loss_before_income_taxes_Detai

Loss before income taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Before Income Tax Domestic And Foreign [Line Items]
United States	($5,223,749)	($5,328,958)
Foreign	-363,863	-422,236
Loss before income taxes	($5,587,612)	($5,751,194)

Deferred_Tax_Assets_Detail

Deferred Tax Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets:
Net operating loss carryforward	$4,820,500	$5,327,000
Stock-based compensation	1,272,600	907,100
Accruals	240,700	139,800
Research & development tax credits	95,500	0
Other	2,100	2,700
Gross deferred tax assets	6,431,400	6,376,600
Deferred Tax Liabilities:
Intangible assets	-93,200	0
Fixed assets	-8,100	-3,000
Gross deferred tax liabilities	-101,300	-3,000
Net deferred tax assets	6,330,100	6,373,600
Valuation allowance	-6,330,100	-6,373,600
Deferred tax asset, net of valuation allowance	0	0
Changes in valuation allowance	($43,500)	$1,631,300

Income_Tax_Provision_benefit_D

Income Tax Provision (benefit) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current	$0	$0
Deferred	38,921	-1,459,584
State and local:
Current	0	0
Deferred	4,579	-171,716
Income tax provision (benefit) before change in valuation allowance	43,500	-1,631,300
Change in valuation allowance	-43,500	1,631,300
Income tax provision (benefit)	$0	$0

Statutory_Federal_Income_Tax_R

Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Tax benefit at federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal benefit	-4.00%	-4.00%
Permanent differences	0.80%	5.80%
Research & development tax credits	-1.80%	0.00%
Impact of Section 382 limit	41.20%	0.00%
True-ups and other	-1.40%	1.60%
Change in valuation allowance	-0.80%	30.60%
Effective income tax rate	0.00%	0.00%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jan. 23, 2015

Oct. 07, 2014

Aug. 13, 2014

Feb. 04, 2014

Jul. 27, 2014

Feb. 20, 2014

Nov. 30, 2013

Jan. 20, 2011

Dec. 31, 2014

Dec. 31, 2013

Mar. 12, 2014

Oct. 08, 2014

Jun. 27, 2014

Oct. 04, 2010

Sep. 24, 2014

Jul. 23, 2014

Jun. 16, 2014

Oct. 23, 2014

Oct. 31, 2014

Mar. 12, 2014

Aug. 27, 2014

Jun. 15, 2012

9-May-14

Mar. 14, 2014

Jul. 02, 2013

Jun. 10, 2013

Mar. 27, 2013

Jul. 22, 2014

Dec. 23, 2013

Mar. 20, 2013

Mar. 22, 2013

Feb. 11, 2014

Aug. 25, 2014

sqft

Commitments and Contingencies Disclosure [Line Items]

Grant date value

$15,000

$67,830

$124,200

Warrant exercisable term

3 years

Lease Expiration Date

31-Jan-14

Lease Rent Second Year

6,234

Lease Rent Third Year

6,422

Research and Development Expense

1,430,614

1,594,054

Accounts Payable and Accrued Liabilities, Total

43,000

353,000

Stock issued during period, value, issued for services

48,388

Stock-based compensation, stock option granted

500,000

10,575,000

1,145,000

Common stock exercise price

$0.32

$0.41

$0.68

Number of shares called by warrants

190,000

402,500

Initial year Salary

25,000

Percentage Of Increase Salary

28.00%

Employee-related Liabilities

574,278

542,535

Salaries, Wages and Officers Compensation, Total

565,000

Loss Contingency, Damages Paid, Value

193,000

Loss contingency damages paid value, warrants issued

80,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

Monthly Payments for Leasing

962

Stock Issued During Period, Shares, New Issues

550,000

Leasehold Improvements, Gross

103,582

0

Rent Expense

20,380

99,175

Professional Fees

1,310,121

779,462

Monthly Payments under Consulting Agreements

15,000

10,000

Monthly Escalating Payments under Consulting Agreements

10,000

Warrants Issued During Period, Number of Warrants

100,000

Share Based Compensation

1,360,296

812,647

Security Deposit

45,900

0

Loss Contingency Damages Paid Value Per Year

52,000

Loss Contingency, Allegations

The action is associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.

Warrants Issue One [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants

100,000

Warrants Issued During Period, Exercise Price at Issuance Date

$0.53

0.53

Warrants Issue Two [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants

280,000

Warrants Issued During Period, Exercise Price at Issuance Date

$0.53

0.53

Warrants Issue Three [Member]

Commitments and Contingencies Disclosure [Line Items]

Warrants Issued During Period, Number of Warrants

20,000

Warrants Issued During Period, Exercise Price at Issuance Date

$1.50

1.5

Chief Medical Advisor [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted

300,000

Common stock exercise price

$0.65

Monthly Payments under Consulting Agreements

10,000

15,000

Monthly Escalating Payments under Consulting Agreements

20,000

20,000

Warrant [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

23,270

23,270

Allocated Share-Based Compensation Expense

30,096

Common Stock [Member]

Commitments and Contingencies Disclosure [Line Items]

Stock Issued During Period, Shares, Other

595,455

Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

80,000

Minimum

Commitments and Contingencies Disclosure [Line Items]

Warrants exercise price

$0.30

$1.50

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.50

$0.94

Maximum

Commitments and Contingencies Disclosure [Line Items]

Warrants exercise price

$0.75

$4

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.75

$2.50

Director

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

600,000

Grant date value

144,000

Stock options granted exercise price per share

$0.28

Number of shares vest on first anniversary of date of grant

200,000

Number of shares vest on second anniversary of date of grant

200,000

Number Of Shares Vest On Third Anniversary Of Date Of Grant

200,000

Chief Executive Officer

Commitments and Contingencies Disclosure [Line Items]

Employee-related Liabilities

25,000

Salaries, Wages and Officers Compensation, Total

450,000

600,000

600,000

Salary Reduced

450,000

360,000

Salary Bonus

300,000

Chief Executive Officer | Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

450,000

Salary Reduced

400,000

Consultant

Commitments and Contingencies Disclosure [Line Items]

Stock issued during period shares for services

30,000

Stock issued during period, value, issued for services

33,000

Stock-based compensation, stock option granted

75,000

60,000

Common stock exercise price

$0.33

$0.39

Number of shares immediately vest on date of grants

150,000

Non Employee Director Awards

Commitments and Contingencies Disclosure [Line Items]

Accounts Payable and Accrued Liabilities, Total

105,000

130,000

Board of Directors

Commitments and Contingencies Disclosure [Line Items]

Salaries, Wages and Officers Compensation, Total

80,000

Compensation Paid To Directors Aggregate Amount

30,000

Compensation Paid To Directors Instalment Amount

50,000

Share Based Compensation

96,250

Employees and Directors

Commitments and Contingencies Disclosure [Line Items]

Grant date value

15,000

Stock issued during period, value, issued for services

5,000

Stock-based compensation, stock option granted

36,786

5,950,000

2,415,000

Common stock exercise price

$0.33

Monthly Payments under Consulting Agreements

10,000

Employees and Directors | Minimum

Commitments and Contingencies Disclosure [Line Items]

Common stock exercise price

0.53

Employees and Directors | Maximum

Commitments and Contingencies Disclosure [Line Items]

Common stock exercise price

0.65

Business Advisory Services

Commitments and Contingencies Disclosure [Line Items]

Stock-based compensation, stock option granted

300,000

Business Advisory Services | Extension 1

Commitments and Contingencies Disclosure [Line Items]

Warrant exercisable term

5 years

Marketing Consulting Services

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

250,000

Exercise price of warrant

$1

Marketing Consulting Services | Consultant

Commitments and Contingencies Disclosure [Line Items]

Contractual Obligation

65,000

Consulting Expense In Shares

500,000

Business Advisory Services Immediately Vesting

Commitments and Contingencies Disclosure [Line Items]

Consulting expense

75,000

16-Aug-15

Commitments and Contingencies Disclosure [Line Items]

Number of shares vest on first anniversary of date of grant

150,000

16-Aug-16

Commitments and Contingencies Disclosure [Line Items]

Number of shares vest on second anniversary of date of grant

150,000

Assignment Agreement

Commitments and Contingencies Disclosure [Line Items]

Cash payment in exchange for patents

15,000

Percentage of royalty agreed to be paid

5.00%

Royalty Period

20 years

Research and Development Arrangement

Commitments and Contingencies Disclosure [Line Items]

Cash payment in exchange for patents

500,000

Percentage of royalty agreed to be paid

5.00%

Royalty Period

20 years

Research and Development Expense

264,000

500,000

Professional Fees

323,336

208,335

Accrued Professional Fees

104,168

Gain On Settlement Related To Agreement

166,668

Agreement Expiration Date

14-Jun-15

Research and Development Arrangement | Minimum

Commitments and Contingencies Disclosure [Line Items]

Fees payable for services per month

20,000

Research and Development Arrangement | Maximum

Commitments and Contingencies Disclosure [Line Items]

Fees payable for services per month

41,667

Marketing Consulting Services Agreement

Commitments and Contingencies Disclosure [Line Items]

Warrant exercisable term

5 years

Consulting expense

82,500

120,000

Marketing Consulting Services Agreement | Warrant [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

37,500

Marketing Consulting Services Agreement | Common Stock [Member]

Commitments and Contingencies Disclosure [Line Items]

Grant date value

110,000

Business Advisory Services | Extension 1

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

250,000

Exercise price of warrant

$1

Grant date value

37,500

Additional Monthly Fee For Services Rendered

16,667

Business Advisory Services | Extension 2

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

100,000

Exercise price of warrant

$0.50

Grant date value

17,000

Additional Monthly Fee For Services Rendered

15,000

Consulting expense

150,000

120,000

Chief Executive Officer Employment Agreements

Commitments and Contingencies Disclosure [Line Items]

Restructuring Reserve, Current

175,000

Scientific Advisory Services

Commitments and Contingencies Disclosure [Line Items]

Grant date value

5,860

47,960

45,900

Warrant exercisable term

10 years

5 years

10 years

5 years

10 years

Recognized granted fair value award

2,056

Total options granted

300,000

25,000

100,000

5,000

60,000

Stock options granted exercise price per share

$0.28

$0.50

$1

$1

$1.50

Number of shares immediately vest on date of grants

81,000

5,000

30,000

Number of shares vest on first anniversary of date of grant

12,500

50,000

Number of shares vest on second anniversary of date of grant

12,500

50,000

30,000

Other

Commitments and Contingencies Disclosure [Line Items]

Warrant issued for the purchase of common stock

10,000

100,000

10,000

100,000

Grant date value

1,500

16,770

6,600

59,000

Warrant exercisable term

5 years

5 years

3 years

5 years

Additional vested common stock shares

474,373

129,537

Additional Vested Common Stock Value

159,837

77,555

Warrants exercise price

$0.75

$2

$1.50

$4

Stem Cell Treatment Company

Commitments and Contingencies Disclosure [Line Items]

Monthly Payments for Leasing

100

Payments for Leasing Per Day

3,750

Melville Lease

Commitments and Contingencies Disclosure [Line Items]

Number of shares called by warrants

142,100

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.50

Land Subject to Ground Leases

6,800

Land Lease Term

63 months

Stock Issued During Period, Shares, Other

284,200

Description Of Leasing Arrangement Consideration

(i) $60,000 towards the leasehold improvements of the leased premises and (ii) $11,050 of prepaid rent for the fifth month of the lease.

Stock Issued During Period, Shares, New Issues

71,050

Leasehold Improvements, Gross

60,000

Prepaid Rent

11,050

Security Deposit

45,900

Melville Lease | Minimum

Commitments and Contingencies Disclosure [Line Items]

Accrued Rent

132,600

Melville Lease | Maximum

Commitments and Contingencies Disclosure [Line Items]

Accrued Rent

$149,260

Stockholders_Deficiency_Additi

Stockholders' Deficiency - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended		0 Months Ended	6 Months Ended	1 Months Ended					0 Months Ended
	Aug. 13, 2014	Feb. 20, 2014	Nov. 27, 2013	Dec. 31, 2014	Dec. 31, 2013	Oct. 04, 2013	Dec. 30, 2014	Nov. 17, 2014	Oct. 27, 2014	Oct. 23, 2014	Mar. 12, 2014	Sep. 24, 2014	Jun. 16, 2014	Dec. 19, 2014	Apr. 15, 2013	8-May-14	Jan. 01, 2015	Feb. 18, 2014
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)	550,000
Sales of common stock and warrants for cash				$2,605,000	$905,000
Warrants to purchase common stock				2,330,693	403,590
Warrants aggregate grant date fair value				389,608	224,313
Share granted vested						490,000					831,669
Weighted average estimated fair value of stock options granted				$0.27	$0.26
Stock-based compensation, stock option granted		500,000		10,575,000	1,145,000
Stock-based compensation, stock options granted, exercise price		$0.32		$0.41	$0.68
Common stock, Authorized				200,000,000	200,000,000									20,000,000	100,000,000
Common stock, par value				$0.00	$0.00
Preferred stock, Authorized				5,000,000	5,000,000									1,000,000
Preferred stock, par value				$0.01	$0.01
Proceeds from Warrant Exercises				113,000	505,809
Warrant modification charge				50,035	214,912
Warrant redemption terms			The terms of the newly issued warrant permit the Company to redeem the new warrant for a total of $1.00 if the common stock of the Company trades above $1.25 for five consecutive trading days.
Received non-interest bearing advances from officer				60,055
Repayments Short Term Advances				60,055
Debt Instrument, Face Amount	4,000,000			7,500
Bermuda Lender [Member] | Research and Development Arrangement [Member]
Stockholders Equity Note Disclosure [Line Items]
Debt Instrument Prepayments of Debt				266,297
Debt Instrument, Face Amount																177,237
Subsequent Event [Member]
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																	200,000,000
Preferred stock, Authorized																	5,000,000
Debt Instrument, Face Amount				50,000
Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price			0.3
Exercise price of redeemable warrant to be issued			0.75
Warrants excluded from computation of weighted average price of warrants granted				376,667
Exercise Price Dollor One Point Five Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted				700,000
Share based compensation shares authorized under stock option plans exercise price				$1.50
Exercise Price Dollor One Point Five Zero | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted					1,686,029
Exercise Price Dollor Zero Point Three Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted				376,667	1,686,029
Legal Counsel
Stockholders Equity Note Disclosure [Line Items]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued						50,000	150,000
Grant date fair value						12,500	33,000
Treasury Stock [Member]
Stockholders Equity Note Disclosure [Line Items]
Proceeds from Warrant Exercises				0	0
Warrant modification charge				0	0
First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested						490,000
Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested											1,589,331
Employee
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted								100,000
Stock-based compensation, stock options granted, exercise price								$0.33
Stock-based compensation, stock options granted, grant date fair value								31,600
Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted									250,000
Stock-based compensation, stock options granted, exercise price									$0.34
Stock-based compensation, stock options granted, grant date fair value									78,500
Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted				36,786						5,950,000	2,415,000
Stock-based compensation, stock options granted, exercise price										$0.33
Stock-based compensation, stock options granted, grant date fair value										1,710,400
Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted						980,000
Stock-based compensation, stock options granted, exercise price						$0.60
Consultant [Member]
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted												75,000	60,000
Stock-based compensation, stock options granted, exercise price												$0.33	$0.39
Stock-based compensation, stock options granted, grant date fair value												20,100	18,600
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share				$0.17	$0.36
Warrants | Warrant Exercise And Reload Program [Member]
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price				$0.30	$0.30
Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense				874,193	647,815
Unrecognized stock-based compensation expense				2,328,885
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition				2 years 7 months 6 days
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense				185,266	26,777
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense				448,189
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value						$199,921					566,483
Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized										20,000,000				100,000,000
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)				8,671,983	840,589
Minimum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share				$0.25	$0.85
Warrants exercise price				$0.30	$1.50
Estimated Forfeitures Related To Option Grants Annual Rate				0.00%	0.00%
Minimum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price											0.53
Minimum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																		6,000,000
Maximum
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share				$0.45	$1.50
Warrants exercise price				$0.75	$4
Estimated Forfeitures Related To Option Grants Annual Rate				5.00%	5.00%
Maximum | Employees and Directors
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, exercise price											0.65
Maximum | Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized																		12,000,000

BlackScholes_Option_Pricing_Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) (Warrants)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.39%	0.34%
Expected term (years)	1 year 11 months 16 days	3 years
Expected volatility	116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.20%	1.68%
Expected term (years)	5 years	5 years
Expected volatility	122.00%	135.00%

Summary_of_Warrant_Activity_De

Summary of Warrant Activity (Detail) (Warrants, USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Warrants
Number of Warrants
Beginning Balance	4,795,890		3,334,800
Granted	3,849,460		3,147,119
Exercised	-376,667		-1,686,029
Forfeited	-20,000		0
Ending Balance	8,248,683		4,795,890
Exercisable	7,548,683
Weighted Average Exercise Price
Beginning Balance	$1.39		$1.69
Granted	$0.70		$1.56
Exercised	$0.30	[1]	$0.30	[1]
Forfeited	$0.50		$0
Ending Balance	$0.90		$1.39
Exercisable	$0.84
Weighted Average Remaining Life In Years
Outstanding	3 years 2 months 12 days
Exercisable	3 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding	$0
Exercisable	$0
[1]	During the year ended December 31, 2013, warrants to purchase an aggregate of 1,686,029 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program. During the year ended December 31, 2014, warrants to purchase an aggregate of 376,667 shares of common stock, with original exercise prices ranging from $1.50 to $4.00 per share, had their exercise prices reduced to $0.30 per share pursuant to the Warrant Exercise and Reload Program.

Summarized_Information_Related

Summarized Information Related to Stock Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	8,248,683
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	7,548,683	[1]
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.3
Warrants Outstanding, Number of Warrants	650,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	650,000
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.4
Warrants Outstanding, Number of Warrants	200,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	200,000
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.5
Warrants Outstanding, Number of Warrants	502,100
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	502,100
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.53
Warrants Outstanding, Number of Warrants	380,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	380,000
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.58
Warrants Outstanding, Number of Warrants	50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	50,000
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.75
Warrants Outstanding, Number of Warrants	4,043,389
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	4,043,389
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.94
Warrants Outstanding, Number of Warrants	50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	50,000
Exercise Price 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1
Warrants Outstanding, Number of Warrants	550,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	550,000
Exercise Price 9
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.5
Warrants Outstanding, Number of Warrants	862,800
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	862,800
Exercise Price 10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.75
Warrants Outstanding, Number of Warrants	20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	20,000
Exercise Price 11
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2
Warrants Outstanding, Number of Warrants	123,530
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	123,530
Exercise Price 12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2.5
Warrants Outstanding, Number of Warrants	20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	20,000
Exercise Price 13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3
Warrants Outstanding, Number of Warrants	36,864
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	36,864
Exercise Price 14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4
Warrants Outstanding, Number of Warrants	60,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	60,000
Exercise Price 15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, Exercise Price Description	Variable
Warrants Outstanding, Number of Warrants	700,000
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years	[1]
Warrants Exercisable, Exercisable Number of Warrants	0	[1]
[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2014.

BlackScholes_Option_Pricing_Mo1

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) (Stock Options)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.50%	1.13%
Expected term (years)	5 years	5 years
Expected volatility	116.00%	132.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.54%	2.66%
Expected term (years)	10 years	10 years
Expected volatility	122.00%	135.00%

Information_Related_to_Stock_O

Information Related to Stock Option Expense (Detail) (Stock Options, USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$874,193		$647,815
Unrecognized expense	2,328,885
Weighted Average Amortization Period (Years)	2 years 7 months 6 days
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	365,825		160,894
Unrecognized expense	654,956
Weighted Average Amortization Period (Years)	2 years 7 months 6 days
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	328,740		251,758
Unrecognized expense	712,551	[1]
Weighted Average Amortization Period (Years)	2 years 6 months
General and administrative
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	179,628		235,163
Unrecognized expense	$961,378
Weighted Average Amortization Period (Years)	2 years 7 months 6 days
[1]	Includes $448,189 of expense that is subject to non-employee mark-to-market adjustments.

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	1 Months Ended	12 Months Ended
	Feb. 20, 2014	Dec. 31, 2014	Dec. 31, 2013
Number of Options
Outstanding		5,043,000	4,018,000
Granted	500,000	10,575,000	1,145,000
Exercised		0	0
Forfeited		-34,000	-120,000
Outstanding		15,584,000	5,043,000
Exercisable		6,371,502
Weighted Average Exercise Price
Outstanding		$1.03	$1.12
Granted	$0.32	$0.41	$0.68
Exercised		$0	$0
Forfeited		$1.31	$0.50
Outstanding		$0.61	$1.03
Exercisable		$0.91
Weighted Average Remaining Life In Years
Outstanding		8 years 6 months
Exercisable		7 years 7 months 6 days
Intrinsic Value
Outstanding		$979,600
Exercisable		$45,600

Information_Related_to_Stock_O1

Information Related to Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	15,584,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	6,371,502
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.285
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	200,000
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.32
Options Outstanding, Number of Options	500,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.33
Options Outstanding, Number of Options	6,125,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	75,000
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.34
Options Outstanding, Number of Options	250,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.39
Options Outstanding, Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Options Exercisable, Exercisable Number of Options	60,000
Exercise Price 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.5
Options Outstanding, Number of Options	345,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	332,500
Exercise Price 7
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.53
Options Outstanding, Number of Options	40,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	40,000
Exercise Price 8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.6
Options Outstanding, Number of Options	980,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	980,000
Exercise Price 9
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.65
Options Outstanding, Number of Options	2,675,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	1,125,002
Exercise price 10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1
Options Outstanding, Number of Options	131,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years
Options Exercisable, Exercisable Number of Options	131,000
Exercise Price 11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.05
Options Outstanding, Number of Options	2,270,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	2,270,000
Exercise Price 12
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.1
Options Outstanding, Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	2 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price 13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.2
Options Outstanding, Number of Options	10,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options	10,000
Exercise Price 14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.25
Options Outstanding, Number of Options	43,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 10 months 24 days
Options Exercisable, Exercisable Number of Options	43,000
Exercise Price 15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.4
Options Outstanding, Number of Options	350,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Options Exercisable, Exercisable Number of Options	200,000
Exercise price 16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.5
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	900,000

Information_Related_to_Common_

Information Related to Common Stock Award Expense (Detail) (Common Stock Award, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$300,837	$138,055
Unrecognized expense	0
Consulting
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	276,500	111,351
Unrecognized expense	0
Research and development
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	24,337	26,704
Unrecognized expense	$0

Summary_of_Common_Stock_Award_

Summary of Common Stock Award Activity (Detail) (Common Stock Award, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Common Stock Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	0	0
Number of Shares, Granted	1,943,747	239,537
Number of Shares, Vested	-1,943,747	-239,537
Numberof Shares, Forfeited	0	0
Number of Shares, Ending Balance	0	0
Weighted Average Grant Date Fair Value, Beginning Balance	$0	$0
Weighted Average Grant Date Fair Value, Granted	$0.26	$0.58
Weighted Average Grant Date Fair Value, Vested	($0.26)	$0.58
Weighted Average Grant Date Fair Value, Forfeited	$0	$0
Weighted Average Grant Date Fair Value, Ending Balance	$0	$0
Total Grant Date Fair Value, Beginning Balance	$0	$0
Total Grant Date Fair Value, Granted	511,886	138,055
Total Grant Date Fair Value, Vested	-511,886	-138,055
Total Grant Date Fair Value, Forfeited	0	0
Total Grant Date Fair Value, Ending Balance	$0	$0

Subsequent_Events_Additional_I

Subsequent Events- Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Mar. 09, 2015

Jan. 23, 2015

Oct. 07, 2014

Aug. 13, 2014

Feb. 20, 2014

Dec. 31, 2014

Dec. 31, 2013

Mar. 26, 2013

Feb. 09, 2015

Mar. 12, 2014

Sep. 24, 2014

Jul. 23, 2014

Jun. 16, 2014

Dec. 02, 2014

2-May-14

Dec. 18, 2013

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

100,000

Warrants Issued During Period, Exercise Price

$0.47

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

500,000

10,575,000

1,145,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.32

$0.41

$0.68

Stock Issued During Period, Shares, New Issues

550,000

Stock Issued During Period, Value, Issued for Services

$48,388

Debt Instrument, Face Amount

4,000,000

7,500

Received non-interest bearing advances from officer

60,055

Repayments Short Term Advances

60,055

Severance Payment

125,000

Bermuda Lender [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

600,000

Stock Issued During Period, Value, New Issues

480,000

Bermuda Lender [Member] | Research and Development Arrangement [Member]

Subsequent Event [Line Items]

Debt Instrument Prepayments of Debt

266,297

Employee Stock Option [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

500,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.46

Warrants Issue One [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

100,000

Warrants Issue Two [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

280,000

Warrants Issue Three [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

20,000

Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

105,000

Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

90,000

Consultant

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

75,000

60,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.33

$0.39

Stock Issued During Period, Shares, Issued for Services

30,000

Stock Issued During Period, Value, Issued for Services

33,000

Exchangeable Notes Payable

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

10.00%

12.00%

12.00%

Debt Instrument, Increase, Accrued Interest

3,646

Exchangeable Notes Payable | Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.22

Exchangeable Notes Payable | Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.19

Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues

5,000

Notes Payable

Subsequent Event [Line Items]

Debt Instrument, Increase, Accrued Interest

13,565

Notes Payable | Maximum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.28

Notes Payable | Minimum [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.14

Chief Medical Advisor [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

300,000

Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price

$0.65

Subsequent Event

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

12.00%

Sale of Stock, Price Per Share

$0.25

Debt Instrument, Face Amount

50,000

Proceeds from Convertible Debt

30,000

Debt Instrument, Convertible, Conversion Price

$0.10

Debt Instrument Percentage For Fair Value

55.00%

Debt Instrument, Increase, Accrued Interest

5,984

Sale of Stock, Number of Shares Issued in Transaction

222,245

Warrant Issued To Purchase Common Stock

80,000

Investment Warrants, Exercise Price

$0.75

Subsequent Event | In Process Research and Development [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

177,234

Subsequent Event | Japanese Pharmaceutical Company [Member]

Subsequent Event [Line Items]

Payments for (Proceeds from) Other Investing Activities

50,000

Subsequent Event | Maximum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

$0.75

Subsequent Event | Minimum [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Exercise Price

$0.40

Subsequent Event | Chief Executive Officer [Member]

Subsequent Event [Line Items]

Annual Salary

400,000

Description for annual bonus of each year

The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary

Description for Chief Executive Officer receive severance amount one

the CEO would be entitled to receive severance in an amount equal to one time his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus).

Description for Chief Executive Officer receive severance amount two

the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).

Subsequent Event | Investors [Member]

Subsequent Event [Line Items]

Warrants Issued During Period, Number of Warrants

850,833

Stock Issued During Period, Shares, New Issues

2,703,333

Stock Issued During Period, Value, New Issues

801,000

Subsequent Event | Investors [Member] | Maximum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.30

Subsequent Event | Investors [Member] | Minimum [Member]

Subsequent Event [Line Items]

Sale of Stock, Price Per Share

$0.25

Subsequent Event | Consultants [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

270,295

Stock Issued During Period, Value, Issued for Services

$73,528

Subsequent Event | Consultants [Member] | Immediately Vesting [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

12,500

Subsequent Event | Consultants [Member] | Vesting Over One Year [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

12,500

Subsequent Event | Consultants [Member] | Vesting Over Three Months [Member]

Subsequent Event [Line Items]

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

75,000